# PDUFA dates August 2025: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2025-08

> 497 FDA catalysts are dated in August 2025, including 24 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in August 2025?

PDUFA dates in August 2025: REDEMPLO (plozasiran, ARWR) on August 7, 2025; LNZ100 (LENZ) on August 8, 2025; INS1201 (INSM) on August 12, 2025; BRINSUPRI® (brensocatib, INSM) on August 12, 2025; Tonix Pharmaceuticals Holding Corp. (TNXP) on August 15, 2025; levosimendan (TNXP) on August 15, 2025; and 18 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2025-08)

Source: Press release filed with the SEC (EX-99), accession 0000879407-25-000010, https://www.sec.gov/Archives/edgar/data/879407/000087940725000010/a991complaint.htm (retrieved 2026-11-12). Last confirmed 2025-09-12. Cite: https://sec-api.dev/fda-calendar/2025-08#answer

## PDUFA dates in August 2025

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| August 7, 2025 | ARROWHEAD PHARMACEUTICALS, INC. | ARWR | REDEMPLO (plozasiran) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940725000010/a991complaint.htm) |
| August 8, 2025 | LENZ Therapeutics, Inc. | LENZ | LNZ100 | presbyopia | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/a991q225pressrelease.htm) |
| August 12, 2025 | INSMED Inc | INSM | INS1201 |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm) |
| August 12, 2025 | INSMED Inc | INSM | BRINSUPRI® (brensocatib) | Bronchiectasis Remains | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125005570/ef20044166_ex99-1.htm) |
| August 15, 2025 | Tonix Pharmaceuticals Holding Corp. | TNXP |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125009199/ex99-01.htm) |
| August 15, 2025 | Tonix Pharmaceuticals Holding Corp. | TNXP | levosimendan |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125011053/ex99-01.htm) |
| August 18, 2025 | REGENXBIO Inc. | RGNX | clemidsogene lanparvovec | Mucopolysaccharidosis II | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590877/000095017025109829/rgnx-20250818.htm) |
| August 18, 2025 | Jazz Pharmaceuticals plc | JAZZ | Modeyso (dordaviprone) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000119312525087233/d887871dex991.htm) |
| August 18, 2025 | Ultragenyx Pharmaceutical Inc. | RARE | FAYUVI (rebisufligene etisparvovec) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-ex99_1.htm) |
| August 19, 2025 | PTC THERAPEUTICS, INC. | PTCT |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/tmb-20250807xex99d1.htm) |
| August 19, 2025 | PTC THERAPEUTICS, INC. | PTCT | vatiquinone |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070081/000155837025010796/tmb-20250630x10q.htm) |
| August 19, 2025 | REGENERON PHARMACEUTICALS, INC. | REGN |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm) |
| August 19, 2025 | Larimar Therapeutics, Inc. | LRMR | SKYCLARYS® (omaveloxolone) | children and adults living with FA | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm) |
| August 21, 2025 | IONIS PHARMACEUTICALS INC | IONS | DAWNZERA™ (donidalorsen) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm) |
| August 27, 2025 | PRECIGEN, INC. | PGEN | zopapogene imadenovec |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1356090/000135609025000024/pgen-20250630.htm) |
| August 27, 2025 | Outlook Therapeutics, Inc. | OTLK |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm) |
| August 27, 2025 | Telix Pharmaceuticals Ltd | TLX | girentuximab |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm) |
| August 27, 2025 | PRECIGEN, INC. | PGEN |  | with Recurrent Respiratory Papillomatosis | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010325006004/dp228863_ex9901.htm) |
| August 27, 2025 | Outlook Therapeutics, Inc. | OTLK | MVASI® (bevacizumab) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm) |
| August 28, 2025 | Travere Therapeutics, Inc. | TVTX | FILSPARI (sparsentan) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/aex991_2024q4x10xkearnings.htm) |
| August 29, 2025 | Sanofi | SNY | Wayrilz (rilzabrutinib) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312524278124/d913939dex992.htm) |
| August 31, 2025 | CAPRICOR THERAPEUTICS, INC. | CAPR |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109298/capr-20250930x10q.htm) |
| August 31, 2025 | BIOGEN INC. | BIIB | LEQEMBI (lecanemab) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504525000033/biib-20250630.htm) |
| August 31, 2025 | CAPRICOR THERAPEUTICS, INC. | CAPR | deramiocel | Duchenne muscular dystrophy | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm) |

## All catalysts in August 2025

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 1, 2025 | [ARDELYX, INC. earnings report](https://sec-api.dev/companies/ardx/catalysts) | ARDX |  | completed | "Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1437402/000162828025037441/ardx-20250630xexhibit991.htm)) |
| August 1, 2025 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "(Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported second quarter 2025 financial results along with a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465925072992/tm2522209d1_ex99-1.htm)) |
| August 1, 2025 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000157056225000094/q22025eolsex991.htm)) |
| August 1, 2025 | [Moderna, Inc. FDA approval](https://sec-api.dev/companies/mrna/catalysts) | MRNA | lower respiratory tract disease | completed, approved | "Additionally, Moderna recently announced that the FDA has approved mRESVIA (mRNA-1345), expanding the previous indication, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000041/exhibit9912025q2pressrelea.htm)) |
| August 1, 2025 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000041/exhibit9912025q2pressrelea.htm)) |
| August 1, 2025 | [REGENERON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/regn/catalysts) | REGN |  | completed | "Tarrytown, New York (August 1, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000017/exhibit991q22025.htm)) |
| August 1, 2025 | [DARZALEX (daratumumab) primary completion](https://sec-api.dev/pdufa/daratumumab) | JNJ | Multiple Myeloma | completed | "NCT05083169 (A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-01 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05083169)) |
| August 1, 2025 | [Luspatercept primary completion](https://sec-api.dev/pdufa/luspatercept) | BMY | Beta-thalassemia | completed | "NCT05567458 (A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-01 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05567458)) |
| August 3, 2025 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "the risk that the reported financial results will differ from the estimates provided in this press release" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312525172207/d113174dex991.htm)) |
| August 4, 2025 | [ROCKET PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | completed | "Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036125029582/ef20053509_ex99-1.htm)) |
| August 4, 2025 | [Krystal Biotech, Inc. earnings report](https://sec-api.dev/companies/krys/catalysts) | KRYS |  | completed | "PITTSBURGH, August 4, 2025 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today reported financial results for the second quarter ending June 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000078/a2q25exhibit991pr.htm)) |
| August 4, 2025 | [VERTEX PHARMACEUTICALS INC / MA earnings report](https://sec-api.dev/companies/vrtx/catalysts) | VRTX |  | completed | "Vertex Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/ex-991_q22025.htm)) |
| August 4, 2025 | [CRISPR Therapeutics AG earnings report](https://sec-api.dev/companies/crsp/catalysts) | CRSP |  | completed | "CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1674416/000095017025102027/crsp-ex99_1.htm)) |
| August 4, 2025 | [BRIUMVI® (ublituximab) earnings report](https://sec-api.dev/pdufa/ublituximab) | TGTX |  | completed | "TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001316/000143774925024480/ex_846995.htm)) |
| August 4, 2025 | [Praxis Precision Medicines, Inc. earnings report](https://sec-api.dev/companies/prax/catalysts) | PRAX |  | completed | "Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954825000094/praxisq22025pr.htm)) |
| August 4, 2025 | [Twist Bioscience Corp earnings report](https://sec-api.dev/companies/twst/catalysts) | TWST |  | completed | "Twist Bioscience Reports Fiscal Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581280/000158128025000006/twst-20250630xex991.htm)) |
| August 4, 2025 | [Arbutus Biopharma Corp earnings report](https://sec-api.dev/companies/abus/catalysts) | ABUS |  | completed | "Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1447028/000117184325005076/exh_991.htm)) |
| August 4, 2025 | [Syndax Pharmaceuticals Inc earnings report](https://sec-api.dev/companies/sndx/catalysts) | SNDX |  | completed | "Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_1.htm)) |
| August 4, 2025 | [Axsome Therapeutics, Inc. earnings report](https://sec-api.dev/companies/axsm/catalysts) | AXSM |  | completed | "Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1579428/000095017025101624/axsm-ex99_1.htm)) |
| August 4, 2025 | [BIOMARIN PHARMACEUTICAL INC earnings report](https://sec-api.dev/companies/bmrn/catalysts) | BMRN |  | completed | "BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance1 for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/earningsrelease-04aug25ex9.htm)) |
| August 4, 2025 | [PROTHENA CORP PUBLIC LTD CO earnings report](https://sec-api.dev/companies/prta/catalysts) | PRTA |  | completed | "Prothena Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1559053/000155905325000029/exhibit991q22025earningsre.htm)) |
| August 4, 2025 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325004977/exh_991.htm)) |
| August 4, 2025 | [Inmune Bio, Inc. earnings report](https://sec-api.dev/companies/inmb/catalysts) | INMB |  | completed | "Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the quarter ended June" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1711754/000121390025073089/ea025192101ex99-1_inmune.htm)) |
| August 4, 2025 | [TLX250 complete response letter (CRL)](https://sec-api.dev/pdufa/tlx250) | TLX |  | completed, complete response letter | "In August 2025, the FDA issued a Complete Response Letter ("CRL"), citing deficiencies relating to the Chemistry, Manufacturing, and Controls ("CMC") package." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm)) |
| August 4, 2025 | [Tinlarebant primary completion](https://sec-api.dev/pdufa/tinlarebant) | BLTE | Stargardt Disease 1 | completed | "NCT05244304 (Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-04 (ACTUAL); Lead Sponsor Belite Bio, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05244304)) |
| August 4, 2025 | [RHUPH20 primary completion](https://sec-api.dev/pdufa/rhuph20) | BMY | Melanoma | completed | "NCT05625399 (A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-04 (ACTUAL); Lead Sponsor Bristol-Myers Squibb; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05625399)) |
| August 5, 2025 | [Amneal Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amrx/catalysts) | AMRX |  | completed | "AMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723128/000172312825000037/amrx-q22025ex991.htm)) |
| August 5, 2025 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the Second Quarter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465925073929/tm2522571d1_ex99-1.htm)) |
| August 5, 2025 | [Cogent Biosciences, Inc. earnings report](https://sec-api.dev/companies/cogt/catalysts) | COGT |  | completed | "WALTHAM, Mass. and BOULDER, Colo., August 5, 2025 - Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000095017025102433/cogt-ex99_1.htm)) |
| August 5, 2025 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2025 FINANCIAL RESULTS; UPDATES KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/ex_831554.htm)) |
| August 5, 2025 | [Lipocine Inc. earnings report](https://sec-api.dev/companies/lpcn/catalysts) | LPCN |  | completed | "Announces Financial Results for the Second Quarter Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1535955/000149315225011589/ex99-1.htm)) |
| August 5, 2025 | [Ultragenyx Pharmaceutical Inc. earnings report](https://sec-api.dev/companies/rare/catalysts) | RARE |  | completed | "Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/rare-ex99_1.htm)) |
| August 5, 2025 | [Pacira BioSciences, Inc. earnings report](https://sec-api.dev/companies/pcrx/catalysts) | PCRX |  | completed | "Pacira BioSciences Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1396814/000139681425000100/pcrx-6302025x991.htm)) |
| August 5, 2025 | [BEAM-302 earnings report](https://sec-api.dev/pdufa/beam-302) | BEAM |  | completed | "Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1745999/000095017025102389/beam-ex99_1.htm)) |
| August 5, 2025 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036125028821/ef20053161_ex99-1.htm)) |
| August 5, 2025 | [OCULAR THERAPEUTIX, INC earnings report](https://sec-api.dev/companies/ocul/catalysts) | OCUL |  | completed | "Inc. (NASDAQ: OCUL, "Ocular"), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the second quarter ended June 30, 2025, and provided recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_ex99-1.htm)) |
| August 5, 2025 | [Jazz Pharmaceuticals plc earnings report](https://sec-api.dev/companies/jazz/catalysts) | JAZZ |  | completed | "Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000123252425000061/a2q25financialpr.htm)) |
| August 5, 2025 | [Cryoport, Inc. earnings report](https://sec-api.dev/companies/cyrx/catalysts) | CYRX |  | completed | "Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124524/000110465925074314/tm2522626d1_ex99-1.htm)) |
| August 5, 2025 | [HALOZYME THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/halo/catalysts) | HALO |  | completed | "HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1159036/000115903625000033/ex991q220258-k.htm)) |
| August 5, 2025 | [PFIZER INC earnings report](https://sec-api.dev/companies/pfe/catalysts) | PFE |  | completed | "Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/pfe-06292025xex99.htm)) |
| August 5, 2025 | [ImmunityBio, Inc. earnings report](https://sec-api.dev/companies/ibrx/catalysts) | IBRX |  | completed | "ImmunityBio Reports Operational and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326110/000132611025000112/ibrx-202585x8kexhibit991.htm)) |
| August 5, 2025 | [RECURSION PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rxrx/catalysts) | RXRX |  | completed | "Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601830/000160183025000126/exhibit991-q0225.htm)) |
| August 5, 2025 | [Boundless Bio, Inc. earnings report](https://sec-api.dev/companies/bold/catalysts) | BOLD |  | completed | "SAN DIEGO, August 5, 2025 - Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782303/000095017025102386/bold-ex99_1.htm)) |
| August 5, 2025 | [AMGEN INC earnings report](https://sec-api.dev/companies/amgn/catalysts) | AMGN |  | completed | "AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318154/000031815425000054/amgn-20250630earningsrelea.htm)) |
| August 5, 2025 | [BridgeBio Pharma, Inc. earnings report](https://sec-api.dev/companies/bbio/catalysts) | BBIO |  | completed | "PALO ALTO, CA - August 5, 2025 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the second quarter ended June 30, 2025, and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000095017025102985/bbio-ex99_1.htm)) |
| August 5, 2025 | [RHYTHM PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/rytm/catalysts) | RYTM |  | completed | "Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000155837025010176/rytm-20250805xex99d1.htm)) |
| August 5, 2025 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000095017025102387/tngx-ex99_1.htm)) |
| August 5, 2025 | [Corbus Pharmaceuticals Holdings, Inc. earnings report](https://sec-api.dev/companies/crbp/catalysts) | CRBP |  | completed | "Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1595097/000095017025102447/crbp-ex99_1.htm)) |
| August 5, 2025 | [Faeth Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fth/catalysts) | FTH |  | completed | "Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1829802/000119312525173043/d46736dex991.htm)) |
| August 5, 2025 | [Nuvectis Pharma, Inc. earnings report](https://sec-api.dev/companies/nvct/catalysts) | NVCT |  | completed | "Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1875558/000110465925073967/tm2522415d1_ex99-1.htm)) |
| August 5, 2025 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "BRISBANE, Calif., August 5, 2025 - Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/vera-ex99_1.htm)) |
| August 5, 2025 | [Organogenesis Holdings Inc. earnings report](https://sec-api.dev/companies/orgo/catalysts) | ORGO |  | completed | "Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661181/000095017025105032/orgo-ex99_1.htm)) |
| August 5, 2025 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312525174947/rgnx-ex99_1.htm)) |
| August 5, 2025 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811725000069/goss-20250805xexx991.htm)) |
| August 5, 2025 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315225011597/ex99-1.htm)) |
| August 5, 2025 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30, 2025, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000110465925074163/tm2522417d2_ex99-1.htm)) |
| August 5, 2025 | [Harmony Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/hrmy/catalysts) | HRMY |  | completed | "HARMONY BIOSCIENCES REPORTS STRONG Q2 2025 FINANCIAL RESULTS AND REAFFIRMS 2025 REVENUE GUIDANCE; ON TRACK TO ANNOUNCE FRAGILE X TOPLINE DATA FROM PHASE 3 REGISTRATIONAL TRIAL IN Q3 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805xex99d1.htm)) |
| August 5, 2025 | [ADMA BIOLOGICS, INC. earnings report](https://sec-api.dev/companies/adma/catalysts) | ADMA |  | completed | "ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1368514/000114036125029143/ef20053140_ex99-1.htm)) |
| August 5, 2025 | [IDEAYA Biosciences, Inc. earnings report](https://sec-api.dev/companies/idya/catalysts) | IDYA |  | completed | "IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1676725/000095017025102353/idya-ex99_1.htm)) |
| August 5, 2025 | [Adaptive Biotechnologies Corp earnings report](https://sec-api.dev/companies/adpt/catalysts) | ADPT |  | completed | "Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1478320/000095017025103058/adpt-ex99_1.htm)) |
| August 5, 2025 | [Emavusertib earnings report](https://sec-api.dev/pdufa/emavusertib) | CRIS |  | completed | "LEXINGTON, Mass., August 5, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and operating results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000079/a2q25earningspressrelease.htm)) |
| August 5, 2025 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000095017025106525/gyre-ex99_1.htm)) |
| August 5, 2025 | [Biomea Fusion, Inc. earnings report](https://sec-api.dev/companies/bmea/catalysts) | BMEA |  | completed | "Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840439/000095017025103023/bmea-ex99_1.htm)) |
| August 5, 2025 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000091/spyre-20250630xexx991.htm)) |
| August 5, 2025 | [MoonLake Immunotherapeutics earnings report](https://sec-api.dev/companies/mltx/catalysts) | MLTX |  | completed | "MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000016/moonlake-pressreleasexq220.htm)) |
| August 5, 2025 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828025037596/a2q25pressrelease_final.htm)) |
| August 5, 2025 | [Zoetis Inc. earnings report](https://sec-api.dev/companies/zts/catalysts) | ZTS |  | completed | "Zoetis Announces Second Quarter 2025 Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1555280/000155528025000259/exhibit99q22025.htm)) |
| August 5, 2025 | [Ajovy (fremanezumab-vfrm) label expansion decision](https://sec-api.dev/pdufa/fremanezumab-vfrm) | TEVA |  | completed, approved | "BLA761089 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20250805, review_priority PRIORITY; sponsor_name TEVA PHARMS USA; product AJOVY (FREMANEZUMAB-VFRM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761089%22)) |
| August 5, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed | "NCT05007106 (MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05007106)) |
| August 5, 2025 | [HIBSAGO (bepirovirsen) primary completion](https://sec-api.dev/pdufa/bepirovirsen) | GSK | Hepatitis B, Chronic | completed | "NCT05276297 (A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-05 (ACTUAL); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05276297)) |
| August 6, 2025 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000095017025104028/artv-ex99_1.htm)) |
| August 6, 2025 | [CHARLES RIVER LABORATORIES INTERNATIONAL, INC. earnings report](https://sec-api.dev/companies/crl/catalysts) | CRL |  | completed | "WILMINGTON, MA, August 6, 2025 - Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1100682/000110068225000032/crl2q25earningsrelease.htm)) |
| August 6, 2025 | [Keros Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kros/catalysts) | KROS |  | completed | "Keros Therapeutics Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1664710/000166471025000068/exhibit991q22025.htm)) |
| August 6, 2025 | [Structure Therapeutics Inc. earnings report](https://sec-api.dev/companies/gpcr/catalysts) | GPCR |  | completed | "Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the second quarter ended June 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465925074712/tm2522431d1_ex99-1.htm)) |
| August 6, 2025 | [BICYCLE THERAPEUTICS PLC earnings report](https://sec-api.dev/companies/bcyc/catalysts) | BCYC |  | completed | "CAMBRIDGE, England & BOSTON, August 8, 2025 - Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761612/000110465925075435/tm2522885d1_ex99-1.htm)) |
| August 6, 2025 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000155837025010399/srrk-20250806xex99d1.htm)) |
| August 6, 2025 | [NewAmsterdam Pharma Co N.V. earnings report](https://sec-api.dev/companies/nams/catalysts) | NAMS |  | completed | "NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1936258/000095017025103520/nams-ex99_1.htm)) |
| August 6, 2025 | [PTR (ptr) NDA/BLA submission](https://sec-api.dev/pdufa/ptr) | CING |  | completed | "Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CTx-1301(dexmethylphenidate" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000164117225022360/ex99-1.htm)) |
| August 6, 2025 | [Q32 Bio Inc. earnings report](https://sec-api.dev/companies/qttb/catalysts) | QTTB |  | completed | "Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661998/000095017025103526/qttb-ex99_1.htm)) |
| August 6, 2025 | [Schrodinger, Inc. earnings report](https://sec-api.dev/companies/sdgr/catalysts) | SDGR |  | completed | "Schrödinger Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm)) |
| August 6, 2025 | [PERRIGO Co plc earnings report](https://sec-api.dev/companies/prgo/catalysts) | PRGO |  | completed | "Perrigo Reports Second Quarter 2025 Financial Results From Continuing Operations" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1585364/000158536425000120/cy25q2ex991pressrelease.htm)) |
| August 6, 2025 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. Reports second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/ea025204301ex99-1_cormedix.htm)) |
| August 6, 2025 | [Zomedica Corp. earnings report](https://sec-api.dev/companies/zomdf/catalysts) | ZOMDF |  | completed | "Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1684144/000165495425009136/zom_ex991.htm)) |
| August 6, 2025 | [Pulmatrix, Inc. earnings report](https://sec-api.dev/companies/pulm/catalysts) | PULM |  | completed | "Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1574235/000164117225022354/ex99-1.htm)) |
| August 6, 2025 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/pressreleaseex991q22025.htm)) |
| August 6, 2025 | [Upstream Bio, Inc. earnings report](https://sec-api.dev/companies/upb/catalysts) | UPB |  | completed | "Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022626/000095017025103528/upb-ex99_1.htm)) |
| August 6, 2025 | [ARVINAS, INC. earnings report](https://sec-api.dev/companies/arvn/catalysts) | ARVN |  | completed | "Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000136/arvn-20250630xexx991.htm)) |
| August 6, 2025 | [ASSEMBLY BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/asmb/catalysts) | ASMB |  | completed | "Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1426800/000095017025104020/asmb-ex99_1.htm)) |
| August 6, 2025 | [Tenaya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tnya/catalysts) | TNYA |  | completed | "Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858848/000095017025104164/tnya-ex99_1.htm)) |
| August 6, 2025 | [Vir Biotechnology, Inc. earnings report](https://sec-api.dev/companies/vir/catalysts) | VIR |  | completed | "Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1706431/000162828025038329/a20250806-q2ex991earningsr.htm)) |
| August 6, 2025 | [Arcus Biosciences, Inc. earnings report](https://sec-api.dev/companies/rcus/catalysts) | RCUS |  | completed | "Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1724521/000172452125000099/a2025q28kexhibit991.htm)) |
| August 6, 2025 | [BioAge Labs, Inc. earnings report](https://sec-api.dev/companies/bioa/catalysts) | BIOA |  | completed | "BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1709941/000095017025104151/bioa-ex99_1.htm)) |
| August 6, 2025 | [Aligos Therapeutics, Inc. earnings report](https://sec-api.dev/companies/algs/catalysts) | ALGS |  | completed | "Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1799448/000117184325005116/exh_991.htm)) |
| August 6, 2025 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000095017025104015/imnm-ex99_1.htm)) |
| August 6, 2025 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "ROYALTY PHARMA REPORTS SECOND QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525173988/d90343dex991.htm)) |
| August 6, 2025 | [Xencor Inc earnings report](https://sec-api.dev/companies/xncr/catalysts) | XNCR |  | completed | "Xencor Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326732/000132673225000074/xncr-20250806xexx991.htm)) |
| August 6, 2025 | [Emergent BioSolutions Inc. earnings report](https://sec-api.dev/companies/ebs/catalysts) | EBS |  | completed | "EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1367644/000136764425000179/ebs2025-06x30ex99earningsr.htm)) |
| August 6, 2025 | [Protagonist Therapeutics, Inc earnings report](https://sec-api.dev/companies/ptgx/catalysts) | PTGX |  | completed | "("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1377121/000110465925074719/tm2522652d1_ex99-1.htm)) |
| August 6, 2025 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "SERES THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312525173985/d930624dex991.htm)) |
| August 6, 2025 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000131/exhibit991-q22025earningsr.htm)) |
| August 6, 2025 | [Viridian Therapeutics, Inc.\DE earnings report](https://sec-api.dev/companies/vrdn/catalysts) | VRDN |  | completed | "Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312525173983/d20477dex991.htm)) |
| August 6, 2025 | [ANAPTYSBIO, INC earnings report](https://sec-api.dev/companies/anab/catalysts) | ANAB |  | completed | "Anaptys Announces Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1370053/000137005325000063/q22025earningsrelease.htm)) |
| August 6, 2025 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000107/exhibit991tarsus862025pres.htm)) |
| August 6, 2025 | [Innoviva, Inc. earnings report](https://sec-api.dev/companies/inva/catalysts) | INVA |  | completed | "Calif. - August 6, 2025 - Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2025, and highlighted select corporate progress and achievements." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1080014/000110465925074730/tm2522376d1_ex99-1.htm)) |
| August 6, 2025 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000155837025010523/mxct-20250806xex99d1.htm)) |
| August 6, 2025 | [OmniAb, Inc. earnings report](https://sec-api.dev/companies/oabi/catalysts) | OABI |  | completed | "OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000184625325000064/a2025q2ex991.htm)) |
| August 6, 2025 | [VAX-31 earnings report](https://sec-api.dev/pdufa/vax-31) | PCVX |  | completed | "Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm)) |
| August 6, 2025 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/a2025q2_8-kxex991.htm)) |
| August 6, 2025 | [Revolution Medicines, Inc. earnings report](https://sec-api.dev/companies/rvmd/catalysts) | RVMD |  | completed | "Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1628171/000095017025103983/rvmd-ex99_1.htm)) |
| August 6, 2025 | [Zentalis Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/zntl/catalysts) | ZNTL |  | completed | "Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1725160/000172516025000147/zntl_q22025earningspr.htm)) |
| August 6, 2025 | [ACADIA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/acad/catalysts) | ACAD |  | completed | "Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070494/000095017025104092/acad-ex99_1.htm)) |
| August 6, 2025 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "August 6, 2025 (Globe Newswire) — MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000095017025103532/mnkd-ex99_1.htm)) |
| August 6, 2025 | [NOVAVAX INC earnings report](https://sec-api.dev/companies/nvax/catalysts) | NVAX |  | completed | "Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000100069425000031/a2q25earningspressreleasef.htm)) |
| August 6, 2025 | [Entrada Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trda/catalysts) | TRDA |  | completed | "Entrada Therapeutics Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689375/000168937525000041/entradatherapeuticsreports.htm)) |
| August 6, 2025 | [GERON CORP earnings report](https://sec-api.dev/companies/gern/catalysts) | GERN |  | completed | "Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886744/000088674425000048/gern-20250630xexx991.htm)) |
| August 6, 2025 | [Neumora Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nmra/catalysts) | NMRA |  | completed | "Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1885522/000095017025103997/nmra-ex99_1.htm)) |
| August 6, 2025 | [BIO-TECHNE Corp earnings report](https://sec-api.dev/companies/tech/catalysts) | TECH |  | completed | "Minneapolis/August 6, 2025/ Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/842023/000155837025010393/tech-20250806xex99d1.htm)) |
| August 6, 2025 | [LEXICON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/lxrx/catalysts) | LXRX |  | completed | "The Woodlands, Texas, August 6, 2025 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2025, and provided an update on key corporate milestones and accomplishments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282225000042/pressreleaseearningsq208-0.htm)) |
| August 6, 2025 | [Mirum Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/mirm/catalysts) | MIRM |  | completed | "Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759425/000175942525000040/mirm-20250806xexx991.htm)) |
| August 6, 2025 | [SAR447537 primary completion](https://sec-api.dev/pdufa/sar447537) | SNY | Alpha 1-Antitrypsin Deficiency; Emphysema | completed | "NCT05856331 (Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-06 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05856331)) |
| August 7, 2025 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS"" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390025073100/ea025218301ex99-1_nektar.htm)) |
| August 7, 2025 | [ARROWHEAD PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/arwr/catalysts) | ARWR |  | completed | "Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000162828025038867/arwr-202508078kex991.htm)) |
| August 7, 2025 | [GILEAD SCIENCES, INC. earnings report](https://sec-api.dev/companies/gild/catalysts) | GILD |  | completed | "GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209525000030/exhibit991earningspressrel.htm)) |
| August 7, 2025 | [IMMUNIC, INC. earnings report](https://sec-api.dev/companies/imux/catalysts) | IMUX |  | completed | "IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter and six months ended June 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000119380525001164/e664768_ex99-1.htm)) |
| August 7, 2025 | [Aclaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrs/catalysts) | ACRS |  | completed | "Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1557746/000155837025010640/acrs-20250807xex99d1.htm)) |
| August 7, 2025 | [Janux Therapeutics, Inc. earnings report](https://sec-api.dev/companies/janx/catalysts) | JANX |  | completed | "Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817713/000095017025105010/janx-ex99_1.htm)) |
| August 7, 2025 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184325005180/exh_991.htm)) |
| August 7, 2025 | [Rapport Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rapp/catalysts) | RAPP |  | completed | "BOSTON and SAN DIEGO, August 7, 2025 - Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the second quarter ending June 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2012593/000095017025104557/rapp-ex99_1.htm)) |
| August 7, 2025 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000155837025010774/nxtc-20250807xex99d1.htm)) |
| August 7, 2025 | [Black Diamond Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bdtx/catalysts) | BDTX |  | completed | "Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701541/000170154125000029/bdtx-exhibit991_q22025.htm)) |
| August 7, 2025 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000095017025105029/atha-ex99_1.htm)) |
| August 7, 2025 | [LIGAND PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lgnd/catalysts) | LGND |  | completed | "Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/886163/000088616325000047/q22025earningsrelease_ex991.htm)) |
| August 7, 2025 | [INTENSITY THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ints/catalysts) | INTS |  | completed | "Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567264/000156726425000078/ints20250807ex99120250630p.htm)) |
| August 7, 2025 | [Edgewise Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ewtx/catalysts) | EWTX |  | completed | "- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the second quarter of 2025 and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710072/000110465925074987/tm2522645d1_ex99-1.htm)) |
| August 7, 2025 | [Amphastar Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amph/catalysts) | AMPH |  | completed | "Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1297184/000129718425000048/amph-20250807xex99d1.htm)) |
| August 7, 2025 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000095017025104545/glue-ex99_1.htm)) |
| August 7, 2025 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/tm2522769d1_ex99-1.htm)) |
| August 7, 2025 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000155837025010658/mtva-20250807xex99d1.htm)) |
| August 7, 2025 | [Prime Medicine, Inc. earnings report](https://sec-api.dev/companies/prme/catalysts) | PRME |  | completed | "Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1894562/000162828025038617/q220258-kex991xpressrelease.htm)) |
| August 7, 2025 | [Avalo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/avtx/catalysts) | AVTX |  | completed | "Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534120/000162828025038570/ex-9912q2025earningsrelease.htm)) |
| August 7, 2025 | [Cabaletta Bio, Inc. earnings report](https://sec-api.dev/companies/caba/catalysts) | CABA |  | completed | "Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759138/000095017025104570/caba-ex99_1.htm)) |
| August 7, 2025 | [Tectonic Therapeutic, Inc. earnings report](https://sec-api.dev/companies/tecx/catalysts) | TECX |  | completed | "Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1681087/000119312525175567/d36621dex991.htm)) |
| August 7, 2025 | [CYTOKINETICS INC earnings report](https://sec-api.dev/companies/cytk/catalysts) | CYTK |  | completed | "CYTOKINETICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1061983/000095017025104962/cytk-ex99_1.htm)) |
| August 7, 2025 | [Atea Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/avir/catalysts) | AVIR |  | completed | "Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1593899/000119312525175433/d921944dex991.htm)) |
| August 7, 2025 | [Relay Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rlay/catalysts) | RLAY |  | completed | "Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1812364/000095017025105022/rlay-ex99_1.htm)) |
| August 7, 2025 | [Trevi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trvi/catalysts) | TRVI |  | completed | "Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1563880/000095017025105011/trvi-ex99_1.htm)) |
| August 7, 2025 | [Replimune Group, Inc. earnings report](https://sec-api.dev/companies/repl/catalysts) | REPL |  | completed | "Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737953/000110465925074989/tm2522849d1_ex99-1.htm)) |
| August 7, 2025 | [PRECISION BIOSCIENCES INC earnings report](https://sec-api.dev/companies/dtil/catalysts) | DTIL |  | completed | "Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357874/000162828025038592/dtil-20250807xex991.htm)) |
| August 7, 2025 | [PepGen Inc. earnings report](https://sec-api.dev/companies/pepg/catalysts) | PEPG |  | completed | "PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835597/000119312525174982/pepg-ex99_1.htm)) |
| August 7, 2025 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000095017025104547/cgem-ex99_1.htm)) |
| August 7, 2025 | [Quoin Pharmaceuticals Ltd. earnings report](https://sec-api.dev/companies/qnrx/catalysts) | QNRX |  | completed | "ASHBURN, Va., August 7, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases provided a corporate update today on its clinical progress and advocacy initiatives and announced its financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465925075244/tm2522891d1_ex99-1.htm)) |
| August 7, 2025 | [ABCL635 earnings report](https://sec-api.dev/pdufa/abcl635) | ABCL |  | completed | "VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2025 and that dosing has begun in a Phase 1 clinical trial of ABCL635 for the potential treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703057/000162828025038927/q22025earningspressrelease.htm)) |
| August 7, 2025 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774925025438/ex_847128.htm)) |
| August 7, 2025 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000095017025105159/stro-ex99_1.htm)) |
| August 7, 2025 | [Zymeworks Inc. earnings report](https://sec-api.dev/companies/zyme/catalysts) | ZYME |  | completed | "Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765325000047/ex991q22025_earningsxrelea.htm)) |
| August 7, 2025 | [ZUSDURI (mitomycin) earnings report](https://sec-api.dev/pdufa/mitomycin) | URGN |  | completed | "UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774925025242/ex_847591.htm)) |
| August 7, 2025 | [Dianthus Therapeutics, Inc. /DE/ earnings report](https://sec-api.dev/companies/dnth/catalysts) | DNTH |  | completed | "AND REPORTS Q2 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025105002/dnth-ex99_1.htm)) |
| August 7, 2025 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000095017025104587/pmvp-ex99_1.htm)) |
| August 7, 2025 | [Cartesian Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rnac/catalysts) | RNAC |  | completed | "Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368725000098/exhibit991_earningsrelease.htm)) |
| August 7, 2025 | [SANGAMO THERAPEUTICS, INC earnings report](https://sec-api.dev/companies/sgmoq/catalysts) | SGMOQ |  | completed | "RICHMOND, California, August 7, 2025 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2025 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001233/000162828025038855/exhibit-991080725.htm)) |
| August 7, 2025 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000095017025104998/rani-ex99_1.htm)) |
| August 7, 2025 | [Akebia Therapeutics, Inc. earnings report](https://sec-api.dev/companies/akba/catalysts) | AKBA |  | completed | "Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1517022/000151702225000034/q22025pr.htm)) |
| August 7, 2025 | [IRONWOOD PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/irwd/catalysts) | IRWD |  | completed | "(Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2025 results and recent business performance." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1446847/000110465925074972/tm2522671d1_ex99-1.htm)) |
| August 7, 2025 | [INSMED Inc earnings report](https://sec-api.dev/companies/insm/catalysts) | INSM |  | completed | "Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm)) |
| August 7, 2025 | [PTC THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | completed | "PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/tmb-20250807xex99d1.htm)) |
| August 7, 2025 | [LIFECORE BIOMEDICAL, INC. \DE\ earnings report](https://sec-api.dev/companies/lfcr/catalysts) | LFCR |  | completed | "Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1005286/000100528625000106/lfcr-25q4xex991earningsrel.htm)) |
| August 7, 2025 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "XERIS BIOPHARMA REPORTS RECORD FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND RAISES FULL YEAR REVENUE GUIDANCE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709625000130/exh991q22025earningsrelease.htm)) |
| August 7, 2025 | [BioAtla, Inc. earnings report](https://sec-api.dev/companies/bcab/catalysts) | BCAB |  | completed | "BIOATLA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826892/000095017025105000/bcab-ex99_1.htm)) |
| August 7, 2025 | [Prestige Consumer Healthcare Inc. earnings report](https://sec-api.dev/companies/pbh/catalysts) | PBH |  | completed | "Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1295947/000129594725000027/exhibit991fy26-q1earningsr.htm)) |
| August 7, 2025 | [Skye Bioscience, Inc. earnings report](https://sec-api.dev/companies/skye/catalysts) | SKYE |  | completed | "Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/skye-20250630xfinancialres.htm)) |
| August 7, 2025 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000095017025105008/dsgn-ex99_1.htm)) |
| August 7, 2025 | [COGNITION THERAPEUTICS INC earnings report](https://sec-api.dev/companies/cgtx/catalysts) | CGTX |  | completed | "Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1455365/000110465925075268/tm2522152d2_ex99-1.htm)) |
| August 7, 2025 | [Zai Lab Ltd earnings report](https://sec-api.dev/companies/zlab/catalysts) | ZLAB |  | completed | "Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1704292/000162828025038547/zlab-202587x8kex991.htm)) |
| August 7, 2025 | [SENTI-202 earnings report](https://sec-api.dev/pdufa/senti-202) | SNTI |  | completed | "Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000185427025000088/ex991snti2025q125earningsr.htm)) |
| August 7, 2025 | [CytomX Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctmx/catalysts) | CTMX |  | completed | "CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501989/000095017025105053/ctmx-ex99_1.htm)) |
| August 7, 2025 | [Viatris Inc earnings report](https://sec-api.dev/companies/vtrs/catalysts) | VTRS |  | completed | "Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204425000031/exhibit991-2q25earningsrel.htm)) |
| August 7, 2025 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/kura-ex99_1.htm)) |
| August 7, 2025 | [Vistagen Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vtgn/catalysts) | VTGN |  | completed | "Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1411685/000141168525000062/vtgn-20250807xex991.htm)) |
| August 7, 2025 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000095017025104546/amlx-ex99_1.htm)) |
| August 7, 2025 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000155837025010802/chrs-20250807xex99d1.htm)) |
| August 7, 2025 | [IN8BIO, INC. earnings report](https://sec-api.dev/companies/inab/catalysts) | INAB |  | completed | "IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1740279/000095017025104986/inab-ex99_1.htm)) |
| August 7, 2025 | [PUMA BIOTECHNOLOGY, INC. earnings report](https://sec-api.dev/companies/pbyi/catalysts) | PBYI |  | completed | "Puma Biotechnology Reports Second Quarter Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/ex_842991.htm)) |
| August 7, 2025 | [NDV-01 earnings report](https://sec-api.dev/pdufa/ndv-01) | RLMD |  | completed | "Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology-related and central nervous system indications, today reported financial results for the second quarter ended June 30, 2025, announced 6-month follow-up data from the Phase 2 study of NDV-01 in bladder cancer and provided a corporate and pipeline update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1553643/000121390025073130/ea025231001ex99-1_relmada.htm)) |
| August 7, 2025 | [KOMZIFTI (ziftomenib) NDA/BLA acceptance](https://sec-api.dev/pdufa/ziftomenib) | KURA |  | completed | "Enrollment in KOMET-001, a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-m AML, has been completed, and in the second quarter of 2025, the companies announced the FDA's acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-m AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/kura-ex99_1.htm)) |
| August 7, 2025 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000095017025104592/whwk-ex99_1.htm)) |
| August 7, 2025 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312525174954/d909051dex991.htm)) |
| August 7, 2025 | [Ginkgo Bioworks Holdings, Inc. earnings report](https://sec-api.dev/companies/dna/catalysts) | DNA |  | completed | "Ginkgo Bioworks Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1830214/000162828025038981/ex991earningspr.htm)) |
| August 7, 2025 | [Disc Medicine, Inc. earnings report](https://sec-api.dev/companies/iron/catalysts) | IRON |  | completed | "Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816736/000181673625000006/iron-ex99_1.htm)) |
| August 7, 2025 | [MARAVAI LIFESCIENCES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/mrvi/catalysts) | MRVI |  | completed | "MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1823239/000182323925000105/exhibit991-q22025xofficial.htm)) |
| August 7, 2025 | [Adicet Bio, Inc. earnings report](https://sec-api.dev/companies/acet/catalysts) | ACET |  | completed | "Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720580/000095017025104969/acet-ex99_1.htm)) |
| August 7, 2025 | [MBX Biosciences, Inc. earnings report](https://sec-api.dev/companies/mbx/catalysts) | MBX |  | completed | "MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000095017025104602/mbx-ex99_1.htm)) |
| August 7, 2025 | [C4 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cccc/catalysts) | CCCC |  | completed | "C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662579/000162828025038576/cccc-20250807xexx991.htm)) |
| August 7, 2025 | [ELI-002 earnings report](https://sec-api.dev/pdufa/eli-002) | ELTX |  | completed | "Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Recent positive recommendation by the Independent Data Monitoring Committee ("IDMC") to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final analysis focused on disease-free survival ("DFS") expected in Q4 2025 Secured $10 million financing in Q2 2025; Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 final analysis BOSTON, August 7, 2025 — Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate and clinical updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000108/a2025-08x07xxeltxxx2q25f.htm)) |
| August 7, 2025 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312525174958/d14149dex991.htm)) |
| August 7, 2025 | [ELI LILLY & Co earnings report](https://sec-api.dev/companies/lly/catalysts) | LLY |  | completed | "Lilly reports second-quarter 2025 financial results and raises guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/59478/000005947825000202/q225lillysalesandearningsp.htm)) |
| August 7, 2025 | [Immunocore Holdings plc earnings report](https://sec-api.dev/companies/imcr/catalysts) | IMCR |  | completed | "Immunocore reports second quarter financial results and provides a business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671927/000114036125029350/ef20053240_ex99-1.htm)) |
| August 7, 2025 | [Rallybio Corp earnings report](https://sec-api.dev/companies/rlyb/catalysts) | RLYB |  | completed | "Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000108/rlyb-2025087xex991pressrel.htm)) |
| August 7, 2025 | [Phathom Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/phat/catalysts) | PHAT |  | completed | "Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783183/000119312525174943/d907916dex991.htm)) |
| August 7, 2025 | [Elanco Animal Health Inc earnings report](https://sec-api.dev/companies/elan/catalysts) | ELAN |  | completed | "Elanco Animal Health Reports Second Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739104/000173910425000052/elanco-20250630exhibit991.htm)) |
| August 7, 2025 | [REDEMPLO (plozasiran) PDUFA date](https://sec-api.dev/pdufa/plozasiran) | ARWR |  | scheduled | "In April 2025, it announced that "Arrowhead's first commercial launch of plozasiran in familial chylomicronemia [is] planned for Q4 2025 (PDUFA 11/18/25)."18 Similarly, in its quarterly earnings call on August 7, 2025, Arrowhead reported no indications that plozasiran would face delays in regulatory approval, stating: "the cadence of our interactions with US and global regulators has not changed, nor have our expectations of adhering to established timelines."19 Arrowhead told its investors that "U.S. launch preparations are now [in] full swing for plozasiran in FCS and we intend to be launch ready even before our PDUFA date."20 37." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/879407/000087940725000010/a991complaint.htm)) |
| August 7, 2025 | [FATE THERAPEUTICS INC earnings report](https://sec-api.dev/companies/fate/catalysts) | FATE |  | completed | "Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434316/000119312525178947/d452012dex991.htm)) |
| August 7, 2025 | [LISATA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/lsta/catalysts) | LSTA |  | completed | "Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/320017/000032001725000059/ex991earningsrelease2q25.htm)) |
| August 7, 2025 | [Alector, Inc. earnings report](https://sec-api.dev/companies/alec/catalysts) | ALEC |  | completed | "Alector Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1653087/000095017025105023/alec-ex99_1.htm)) |
| August 7, 2025 | [COLLEGIUM PHARMACEUTICAL, INC earnings report](https://sec-api.dev/companies/coll/catalysts) | COLL |  | completed | "Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1267565/000155837025010647/coll-20250807xex99d1.htm)) |
| August 8, 2025 | [Calidi Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/cldi/catalysts) | CLDI |  | completed | "Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/ex99-1.htm)) |
| August 8, 2025 | [CG Oncology, Inc. earnings report](https://sec-api.dev/companies/cgon/catalysts) | CGON |  | completed | "CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1991792/000095017025105487/ck0001991792-ex99_1.htm)) |
| August 8, 2025 | [KALA BIO, Inc. earnings report](https://sec-api.dev/companies/kala/catalysts) | KALA |  | completed | "KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479419/000155837025010850/kala-20250808xex99d1.htm)) |
| August 8, 2025 | [KIORA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/kprx/catalysts) | KPRX |  | completed | "Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372514/000137251425000064/ex991-pressreleasejune3020.htm)) |
| August 8, 2025 | [VEPPANU (vepdegestrant) NDA/BLA acceptance](https://sec-api.dev/pdufa/vepdegestrant) | ARVN | with estrogen receptor positive | completed | "On August 8, 2025, the Company issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has accepted a new drug application ("NDA") for vepdegestrant for the treatment of patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor 2-negative ("HER2-") ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1655759/000165575925000141/arvn-20250808.htm)) |
| August 8, 2025 | [HERON THERAPEUTICS, INC. /DE/ earnings report](https://sec-api.dev/companies/hrtx/catalysts) | HRTX |  | completed | "Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818033/000095017025105474/hrtx-ex99_1.htm)) |
| August 8, 2025 | [LNZ100 PDUFA date](https://sec-api.dev/pdufa/lnz100) | LENZ | presbyopia | completed, approved | "New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/a991q225pressrelease.htm)) |
| August 8, 2025 | [ANI PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/anip/catalysts) | ANIP |  | completed | "ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1023024/000102302425000081/anip-20250808xexx991.htm)) |
| August 8, 2025 | [Entera Bio Ltd. earnings report](https://sec-api.dev/companies/entx/catalysts) | ENTX |  | completed | "Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638097/000117891325002701/exhibit_99-1.htm)) |
| August 8, 2025 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312525178954/d409147dex991.htm)) |
| August 8, 2025 | [Edesa Biotech, Inc. earnings report](https://sec-api.dev/companies/edsa/catalysts) | EDSA |  | completed | "Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1540159/000117184325005235/exh_991.htm)) |
| August 8, 2025 | [REVELATION BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/revb/catalysts) | REVB |  | completed | "Revelation Biosciences, Inc. Announces Financial Results for the three and six months ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810560/000095017025105485/revb-ex99_1.htm)) |
| August 8, 2025 | [EXICURE, INC. earnings report](https://sec-api.dev/companies/xcur/catalysts) | XCUR |  | completed | "Exicure, Inc. Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1698530/000169853025000076/a8kq22025exhibit991.htm)) |
| August 8, 2025 | [Surrozen, Inc./DE earnings report](https://sec-api.dev/companies/srzn/catalysts) | SRZN |  | completed | "Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824893/000095017025105839/srzn-ex99_1.htm)) |
| August 8, 2025 | [Bimatoprost sr primary completion](https://sec-api.dev/pdufa/bimatoprost-sr) | ABBV | Open-Angle Glaucoma; Ocular Hypertension | completed | "NCT03850782 (Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-08 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-11-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03850782)) |
| August 8, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Obesity; Overweight; Type 2 Diabetes | completed | "NCT05872620 (A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-08 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05872620)) |
| August 8, 2025 | [Ltg-001 high dose primary completion](https://sec-api.dev/pdufa/ltg-001) | LTGO | Acute Pain, Postoperative | completed | "NCT06774625 (This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-08 (ACTUAL); Lead Sponsor Latigo Biotherapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06774625)) |
| August 11, 2025 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/eldn-ex99_1.htm)) |
| August 11, 2025 | [Roivant Sciences Ltd. earnings report](https://sec-api.dev/companies/roiv/catalysts) | ROIV |  | completed | "Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1635088/000114036125029998/ef20053385_ex99-1.htm)) |
| August 11, 2025 | [Serina Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ser/catalysts) | SER |  | completed | "Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708599/000170859925000091/ser-20250811xex991_earning.htm)) |
| August 11, 2025 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597925000067/a2025q2bhvnearningsprex991.htm)) |
| August 11, 2025 | [BioCardia, Inc. earnings report](https://sec-api.dev/companies/bcda/catalysts) | BCDA |  | completed | "BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/925741/000143774925025827/ex_850763.htm)) |
| August 11, 2025 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000095017025106533/atra-ex99_1.htm)) |
| August 11, 2025 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774925025814/ex_850337.htm)) |
| August 11, 2025 | [KAMADA LTD FDA approval](https://sec-api.dev/companies/kmda/catalysts) | KMDA |  | completed, approved | "11, 2025 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplement to its existing Biologics License Application (BLA) for Kamada Plasma's collection center in Houston," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567529/000121390025073908/ea025258701ex99-1_kamada.htm)) |
| August 11, 2025 | [4D Molecular Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fdmt/catalysts) | FDMT |  | completed | "4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650648/000095017025106243/fdmt-ex99_1.htm)) |
| August 11, 2025 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | active Sjögren's disease | completed, positive | "Basel, August 11, 2025 - Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1114448/000117184325005290/f6k_081125.htm)) |
| August 11, 2025 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000155837025010974/avbp-20250811xex99d1.htm)) |
| August 11, 2025 | [Sana Biotechnology, Inc. earnings report](https://sec-api.dev/companies/sana/catalysts) | SANA |  | completed | "Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770121/000177012125000009/sana-ex99_1.htm)) |
| August 11, 2025 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000095017025106235/agen-ex99_1.htm)) |
| August 11, 2025 | [Humacyte, Inc. earnings report](https://sec-api.dev/companies/huma/catalysts) | HUMA |  | completed | "Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818382/000181838225000122/huma-20250811xexx991.htm)) |
| August 11, 2025 | [Tonix Pharmaceuticals Holding Corp. earnings report](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125011053/ex99-01.htm)) |
| August 11, 2025 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000095017025106227/kymr-ex99_1.htm)) |
| August 11, 2025 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025011047/capr-20250811xex99d1.htm)) |
| August 11, 2025 | [ENANTA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/enta/catalysts) | ENTA |  | completed | "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312525177941/enta-ex99_1.htm)) |
| August 11, 2025 | [Immunovant, Inc. earnings report](https://sec-api.dev/companies/imvt/catalysts) | IMVT |  | completed | "Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1764013/000176401325000128/exhibit9912025811.htm)) |
| August 11, 2025 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, August 11, 2025 (GlobeNewswire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000095017025106545/olma-ex99_1.htm)) |
| August 11, 2025 | [Cadrenal Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cvkd/catalysts) | CVKD |  | completed | "VEDRA, FL, August 11, 2025 - Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing transformative therapeutics that specifically address limitations of current anticoagulation therapy, today reported its financial results for the second quarter ended June 30, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937993/000121390025074355/ea025264301ex99-1_cadrenal.htm)) |
| August 11, 2025 | [Sionna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sion/catalysts) | SION |  | completed | "Sionna Therapeutics Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2036042/000203604225000044/sion2q25earningsrelease_fi.htm)) |
| August 11, 2025 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000155837025011227/armp-20250811xex99d1.htm)) |
| August 11, 2025 | [Compass Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cmpx/catalysts) | CMPX |  | completed | "Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325005260/exh_991.htm)) |
| August 11, 2025 | [Ivonescimab earnings report](https://sec-api.dev/pdufa/ivonescimab) | SMMT |  | completed | "Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 Ivonescimab in Combination with Chemotherapy Showed Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1599298/000159929825000128/a2025_prx0811xq22025earn.htm)) |
| August 11, 2025 | [Yarrow Bioscience, Inc. earnings report](https://sec-api.dev/companies/yarw/catalysts) | YARW |  | completed | "Inc. (Nasdaq: VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today reported financial results as of and for the quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1566044/000110465925078135/tm2523400d1_ex99-1.htm)) |
| August 11, 2025 | [Theriva (theriva) earnings report](https://sec-api.dev/pdufa/theriva) | TOVX |  | completed | "Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465925075944/tm2522967d1_ex99-1.htm)) |
| August 11, 2025 | [Azitra, Inc. earnings report](https://sec-api.dev/companies/aztr/catalysts) | AZTR |  | completed | "BRANFORD, Conn. - August 11, 2025 — Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended June 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701478/000170147825000041/aztrpressrelease06302025-e.htm)) |
| August 11, 2025 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "Aptevo Therapeutics Reports 2Q25 Financial Results And" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000095017025106246/apvo-ex99_1.htm)) |
| August 11, 2025 | [Septerna, Inc. earnings report](https://sec-api.dev/companies/sepn/catalysts) | SEPN |  | completed | "Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1984086/000095017025106540/sepn-ex99_1.htm)) |
| August 11, 2025 | [Karyopharm Therapeutics Inc. earnings report](https://sec-api.dev/companies/kpti/catalysts) | KPTI |  | completed | "Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1503802/000095017025106236/kpti-ex99_1.htm)) |
| August 11, 2025 | [IRulya Therapeutics Inc. earnings report](https://sec-api.dev/companies/irla/catalysts) | IRLA |  | completed | "SOUTH SAN FRANCISCO, Calif. - August 11, 2025 - Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1662774/000095017025106536/qncx-ex99_1.htm)) |
| August 11, 2025 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390025073937/ea025050901ex99-1_protara.htm)) |
| August 11, 2025 | [Zorevunersen trial start](https://sec-api.dev/pdufa/zorevunersen) | STOK | Dravet syndrome | completed | "On August 11, 2025, Stoke Therapeutics, Inc. (the "Company") and Biogen International GmbH issued a joint press release (the "Press Release") announcing that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1623526/000119312525177433/d64221d8k.htm)) |
| August 11, 2025 | [STANDARD BIOTOOLS INC. earnings report](https://sec-api.dev/companies/lab/catalysts) | LAB |  | completed | "Standard BioTools Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1162194/000095017025106636/lab-ex99_1.htm)) |
| August 11, 2025 | [Denali Therapeutics Inc. earnings report](https://sec-api.dev/companies/dnli/catalysts) | DNLI |  | completed | "Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489925000167/ex991pressreleaseq22025.htm)) |
| August 11, 2025 | [Tempest Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tpst/catalysts) | TPST |  | completed | "Tempest Reports Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1544227/000095017025106544/tpst-ex99_1.htm)) |
| August 11, 2025 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the second quarter ended June 30, 2025, and provided corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380525001175/e664773_ex99-1.htm)) |
| August 11, 2025 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000095017025106534/fgen-ex99_1.htm)) |
| August 11, 2025 | [Xenon Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/xene/catalysts) | XENE |  | completed | "Xenon Reports Second Quarter 2025 Financial Results & Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000095017025106529/xene-ex99_1.htm)) |
| August 11, 2025 | [Neurogene earnings report](https://sec-api.dev/pdufa/neurogene) | NGNE |  | completed | "Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000082/ngne_2q25earningsreleasexf.htm)) |
| August 11, 2025 | [HARROW, INC. earnings report](https://sec-api.dev/companies/hrow/catalysts) | HROW |  | completed | "Announces Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1360214/000149315225021555/ex99-1.htm)) |
| August 11, 2025 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873325000012/q22025-ex991earningsrelease.htm)) |
| August 11, 2025 | [ABECMA (idecabtagene vicleucel) primary completion](https://sec-api.dev/pdufa/idecabtagene-vicleucel) | BMY | Multiple Myeloma | completed | "NCT06045806 (A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-11 (ACTUAL); Lead Sponsor Celgene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045806)) |
| August 11, 2025 | [Test toothpaste primary completion](https://sec-api.dev/pdufa/test-toothpaste) | CL | Dentin Hypersensitivity | completed | "NCT06956599 (Hypersensitivity Reduction Efficacy: 5% Potassium Nitrate Toothpaste Compared to Colgate Cavity Protection Toothpaste): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-11 (ACTUAL); Lead Sponsor Colgate Palmolive." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06956599)) |
| August 12, 2025 | [ZEVRA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/zvra/catalysts) | ZVRA |  | completed | "Zevra Reports Second Quarter 2025 Financial Results and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434647/000162828025039883/zvra-20250812xex991.htm)) |
| August 12, 2025 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000056/ino-63025x8kex991.htm)) |
| August 12, 2025 | [Oric Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/oric/catalysts) | ORIC |  | completed | "ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1796280/000095017025107313/oric-ex99_1.htm)) |
| August 12, 2025 | [Silexion Therapeutics Corp earnings report](https://sec-api.dev/companies/slxn/catalysts) | SLXN |  | completed | "GRAND CAYMAN, Cayman Islands, August 12, 2025 - Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the second quarter ended June 30, 2025, and provided an update on recent business developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/exhibit_99-1.htm)) |
| August 12, 2025 | [Editas Medicine, Inc. earnings report](https://sec-api.dev/companies/edit/catalysts) | EDIT |  | completed | "Editas Medicine Announces Second Quarter 2025 Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650664/000165066425000123/editasmedicinepressrelease.htm)) |
| August 12, 2025 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948025000075/exhibit991-earningsrelease.htm)) |
| August 12, 2025 | [Bicara Therapeutics Inc. earnings report](https://sec-api.dev/companies/bcax/catalysts) | BCAX |  | completed | "Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023658/000202365825000094/pressreleaseq22025.htm)) |
| August 12, 2025 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000095017025106918/ck0001534133-ex99_1.htm)) |
| August 12, 2025 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000095017025107268/cue-ex99_1.htm)) |
| August 12, 2025 | [Aprea Therapeutics, Inc. earnings report](https://sec-api.dev/companies/apre/catalysts) | APRE |  | completed | "Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781983/000155837025011149/apre-20250812xex99d1.htm)) |
| August 12, 2025 | [Korro Bio, Inc. earnings report](https://sec-api.dev/companies/krro/catalysts) | KRRO |  | completed | "Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703647/000095017025106910/krro-ex99_1.htm)) |
| August 12, 2025 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000017/sls-202508128xkexhibit991.htm)) |
| August 12, 2025 | [INS1201 PDUFA date](https://sec-api.dev/pdufa/ins1201) | INSM |  | scheduled | "Prescription Drug User Fee Act (PDUFA) target action date of August 12, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125029343/ef20053237_ex99-1.htm)) |
| August 12, 2025 | [Lyell Immunopharma, Inc. earnings report](https://sec-api.dev/companies/lyel/catalysts) | LYEL |  | completed | "Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806952/000180695225000007/lyel-20250812x8kexx991.htm)) |
| August 12, 2025 | [Citius Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed | "Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for its fiscal third quarter ended June 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1506251/000121390025075034/ea025289901ex99-1_citius.htm)) |
| August 12, 2025 | [Nkarta, Inc. earnings report](https://sec-api.dev/companies/nktx/catalysts) | NKTX |  | completed | "Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787400/000119312525178949/nktx-ex99_1.htm)) |
| August 12, 2025 | [ALX ONCOLOGY HOLDINGS INC earnings report](https://sec-api.dev/companies/alxo/catalysts) | ALXO |  | completed | "ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1810182/000095017025107277/alxo-ex99_1.htm)) |
| August 12, 2025 | [Milestone Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/mist/catalysts) | MIST |  | completed | "Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465925076468/tm2523169d1_ex99-1.htm)) |
| August 12, 2025 | [DiaMedica Therapeutics Inc. earnings report](https://sec-api.dev/companies/dmac/catalysts) | DMAC |  | completed | "DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401040/000143774925026205/ex_851444.htm)) |
| August 12, 2025 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "- Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465925076464/tm2523154d1_ex99-1.htm)) |
| August 12, 2025 | [TherapeuticsMD, Inc. earnings report](https://sec-api.dev/companies/txmd/catalysts) | TXMD |  | completed | "PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED AUGUST 12, 2025, ENTITLED "THERAPEUTICSMD ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/25743/000121390025074975/ea025234801ex99-1_therap.htm)) |
| August 12, 2025 | [VERU INC. earnings report](https://sec-api.dev/companies/veru/catalysts) | VERU |  | completed | "Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/863894/000119312525178463/d59822dex991.htm)) |
| August 12, 2025 | [Coya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/coya/catalysts) | COYA |  | completed | "Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835022/000095017025106932/coya-ex99_1.htm)) |
| August 12, 2025 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., Aug 12, 2025  Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312525178970/d97572dex991.htm)) |
| August 12, 2025 | [Taysha Gene Therapies, Inc. earnings report](https://sec-api.dev/companies/tsha/catalysts) | TSHA |  | completed | "Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525178504/d51118dex991.htm)) |
| August 12, 2025 | [Metagenomi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mgx/catalysts) | MGX |  | completed | "Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785279/000095017025107304/mgx-ex99_1.htm)) |
| August 12, 2025 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000095017025107299/maze-ex99_1.htm)) |
| August 12, 2025 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000177191025000006/adct-20250630pressrelease.htm)) |
| August 12, 2025 | [PROKIDNEY CORP. earnings report](https://sec-api.dev/companies/prok/catalysts) | PROK |  | completed | "ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850270/000095017025107357/prok-ex99_1.htm)) |
| August 12, 2025 | [ATOSSA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/atos/catalysts) | ATOS |  | completed | "Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1488039/000095017025106944/atos-ex99_1.htm)) |
| August 12, 2025 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, IL, August 12, 2025 - Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced second quarter 2025 financial results and recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774925026043/ex_849537.htm)) |
| August 12, 2025 | [Erasca, Inc. earnings report](https://sec-api.dev/companies/eras/catalysts) | ERAS |  | completed | "Erasca Reports Second Quarter 2025 Business Updates and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761918/000119312525178950/eras-ex99_1.htm)) |
| August 12, 2025 | [TSHA-102 trial start](https://sec-api.dev/pdufa/tsha-102) | TSHA |  | completed | "Subsequently, on August 12, 2025, we announced that we commenced site activation activities for the REVEAL pivotal part B trial in accordance with previously aligned upon key design elements, following receipt of a No Objection Letter, or NOL, from Health Canada and feedback from the FDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1806310/000095017025107010/tsha-20250630.htm)) |
| August 12, 2025 | [OnKure Therapeutics, Inc. earnings report](https://sec-api.dev/companies/okur/catalysts) | OKUR |  | completed | "OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1637715/000119312525178978/okur-ex99_1.htm)) |
| August 12, 2025 | [Mereo BioPharma Group plc earnings report](https://sec-api.dev/companies/mreo/catalysts) | MREO |  | completed | "Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719714/000095017025106924/mreo-ex99_1.htm)) |
| August 12, 2025 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "- Journey Medical Corporation (Nasdaq: DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465925076825/tm2523268d1_ex99-1.htm)) |
| August 12, 2025 | [BioXcel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/btaiq/catalysts) | BTAIQ |  | completed | "Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465925076501/tm2523230d1_ex99-1.htm)) |
| August 12, 2025 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341425000088/mlys2025q28kex991.htm)) |
| August 12, 2025 | [Kyverna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kytx/catalysts) | KYTX |  | completed | "Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000095017025107300/kytx-ex99_1.htm)) |
| August 12, 2025 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal third quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390025075014/ea025288401ex99-1_citius.htm)) |
| August 12, 2025 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688525000091/abos-20250812xexx991.htm)) |
| August 12, 2025 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, August 12, 2025 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today reported financial and operating results for the quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/exhibit991-2025q210xqpr.htm)) |
| August 12, 2025 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000155837025011218/ganx-20250812xex99d1.htm)) |
| August 12, 2025 | [AEON Biopharma, Inc. earnings report](https://sec-api.dev/companies/aeon/catalysts) | AEON |  | completed | "AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760725000065/aeon-20250812xex99d1.htm)) |
| August 12, 2025 | [Climb Bio, Inc. earnings report](https://sec-api.dev/companies/clym/catalysts) | CLYM |  | completed | "Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-ex99_1.htm)) |
| August 12, 2025 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "2025 - Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465925076412/tm2523179d1_ex99-1.htm)) |
| August 12, 2025 | [BRINSUPRI® (brensocatib) FDA approval](https://sec-api.dev/pdufa/brensocatib) | INSM | To treat non-cystic fibrosis bronchiectasis | completed, approved | "Brinsupri \| brensocatib \| 8/12/2025 \| To treat non-cystic fibrosis bronchiectasisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| August 12, 2025 | [EP-104 trial start](https://sec-api.dev/pdufa/ep-104) | EPRX |  | completed | "Announced first patient dosed in the Phase 2b placebo-controlled portion of the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000119312525179135/d54647dex993.htm)) |
| August 12, 2025 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985625000060/crbu-20250812xexx991.htm)) |
| August 12, 2025 | [Lineage Cell Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lctx/catalysts) | LCTX |  | completed | "LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/876343/000095017025107314/lctx-ex99_1.htm)) |
| August 12, 2025 | [TScan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tcrx/catalysts) | TCRX |  | completed | "TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783328/000095017025106915/tcrx-ex99_1.htm)) |
| August 12, 2025 | [BRINSUPRI® (brensocatib) PDUFA date](https://sec-api.dev/pdufa/brensocatib) | INSM | Bronchiectasis Remains | completed, approved | "The FDA had previously granted Priority Review to Insmed's NDA for brensocatib and set a target action date of August 12, 2025, under the Prescription" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036125005570/ef20044166_ex99-1.htm)) |
| August 12, 2025 | [VTv Therapeutics Inc. earnings report](https://sec-api.dev/companies/vtvt/catalysts) | VTVT |  | completed | "Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641489/000164148925000051/vtvt-20250630xexx991pressr.htm)) |
| August 12, 2025 | [Passage BIO, Inc. earnings report](https://sec-api.dev/companies/pasg/catalysts) | PASG |  | completed | "PASSAGE BIO REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787297/000155837025011143/pasg-20250812xex99d1.htm)) |
| August 12, 2025 | [Grace Therapeutics, Inc. earnings report](https://sec-api.dev/companies/grce/catalysts) | GRCE |  | completed | "Grace Therapeutics Announces First Quarter 2026 Financial Results," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/ef20053073_ex99-1.htm)) |
| August 12, 2025 | [Stoke Therapeutics, Inc. earnings report](https://sec-api.dev/companies/stok/catalysts) | STOK |  | completed | "Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1623526/000095017025107275/stok-ex99_1.htm)) |
| August 12, 2025 | [Altimmune, Inc. earnings report](https://sec-api.dev/companies/alt/catalysts) | ALT |  | completed | "Altimmune Announces Second Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326190/000155837025011145/alt-20250812xex99d1.htm)) |
| August 12, 2025 | [AUCATZYL (obecabtagene autoleucel) earnings report](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed | "Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates August 12, 2025 at 7:00 AM EDT Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025 Company recently received conditional marketing authorization from U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and conditional European marketing authorization from the European Commission (EC) for AUCATZYL® Follow up data from the FELIX trial demonstrating obe-cel's potential for long-term remission in r/r B-ALL presented at the 2025 European Hematology Association (EHA) Congress Company is on track to initiate Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) by year-end 2025 Conference call to be held today at 08:30 am EDT/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON and GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces its operational and financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046325000064/autlex-991pr120825.htm)) |
| August 12, 2025 | [LYNPARZA® (olaparib) primary completion](https://sec-api.dev/pdufa/olaparib) | MRK | Advanced Solid Neoplasms | completed | "NCT03742895 (Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03742895)) |
| August 12, 2025 | [Bgf mdi hfo 320/14.4/9.6μg primary completion](https://sec-api.dev/pdufa/bgf-mdi-hfo-320-14-4) | AZN | COPD (Chronic Obstructive Pulmonary Disease) | completed | "NCT06075095 (A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-12 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06075095)) |
| August 13, 2025 | [ProPhase Labs, Inc. earnings report](https://sec-api.dev/companies/prph/catalysts) | PRPH |  | completed | "Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/868278/000164117225023344/ex99-1.htm)) |
| August 13, 2025 | [DYADIC INTERNATIONAL INC earnings report](https://sec-api.dev/companies/dyai/catalysts) | DYAI |  | completed | "Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213809/000164117225023496/ex99-1.htm)) |
| August 13, 2025 | [Aardvark Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aard/catalysts) | AARD |  | completed | "Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1774857/000095017025108082/ck0001774857-ex99_1.htm)) |
| August 13, 2025 | [Briquilimab earnings report](https://sec-api.dev/pdufa/briquilimab) | JSPR |  | completed | "NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended June 30, 2025 and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1788028/000121390025075678/ea025299101ex99-1_jasper.htm)) |
| August 13, 2025 | [Kodiak Sciences Inc. earnings report](https://sec-api.dev/companies/kod/catalysts) | KOD |  | completed | "Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000095017025107982/kod-ex99_1.htm)) |
| August 13, 2025 | [Instil Bio, Inc. earnings report](https://sec-api.dev/companies/til/catalysts) | TIL |  | completed | "Instil Bio Reports Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789769/000178976925000079/q2-25er.htm)) |
| August 13, 2025 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm)) |
| August 13, 2025 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000095017025107617/spry-ex99_1.htm)) |
| August 13, 2025 | [Adaptimmune Therapeutics PLC earnings report](https://sec-api.dev/companies/adapy/catalysts) | ADAPY |  | completed | "Adaptimmune Reports Q2 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011304/adap-20250813xex99d1.htm)) |
| August 13, 2025 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000155837025011297/pmn-20250813xex99d1.htm)) |
| August 13, 2025 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/d913327dex991.htm)) |
| August 13, 2025 | [Vireo Growth Inc. earnings report](https://sec-api.dev/companies/vreof/catalysts) | VREOF |  | completed | "Vireo Growth Inc. Announces Second Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771706/000155837025011303/vreof-20250813xex99d1.htm)) |
| August 13, 2025 | [Allogene Therapeutics, Inc. earnings report](https://sec-api.dev/companies/allo/catalysts) | ALLO |  | completed | "Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737287/000173728725000087/allo-20250630xexx991q225.htm)) |
| August 13, 2025 | [Longeveron Inc. earnings report](https://sec-api.dev/companies/lgvn/catalysts) | LGVN |  | completed | "Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1721484/000121390025075679/ea025283701ex99-1_longeveron.htm)) |
| August 13, 2025 | [Connect Biopharma Holdings Ltd earnings report](https://sec-api.dev/companies/cntb/catalysts) | CNTB |  | completed | "Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835268/000183526825000051/cntbq22025earningsrelease.htm)) |
| August 13, 2025 | [Ensysce Biosciences, Inc. earnings report](https://sec-api.dev/companies/ensc/catalysts) | ENSC |  | completed | "Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1716947/000164117225023500/ex99-1.htm)) |
| August 13, 2025 | [BeyondSpring Inc. earnings report](https://sec-api.dev/companies/bysi/catalysts) | BYSI |  | completed | "BeyondSpring Reports Second-Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677940/000117184325005355/exh_991.htm)) |
| August 13, 2025 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036125030822/ef20053851_ex99-1.htm)) |
| August 13, 2025 | [PDS Biotechnology Corp earnings report](https://sec-api.dev/companies/pdsb/catalysts) | PDSB |  | completed | "PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472091/000114036125030701/ef20053853_ex99-1.htm)) |
| August 13, 2025 | [TENAX THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tenx/catalysts) | TENX |  | completed | "Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/34956/000165495425009510/tennx_ex991.htm)) |
| August 13, 2025 | [Indaptus Therapeutics, Inc. earnings report](https://sec-api.dev/companies/indp/catalysts) | INDP |  | completed | "Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1857044/000164117225023332/ex99-1.htm)) |
| August 13, 2025 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS Second QUARTER 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/ex_829965.htm)) |
| August 13, 2025 | [Lantern Pharma Inc. earnings report](https://sec-api.dev/companies/ltrn/catalysts) | LTRN |  | completed | "Pharma Reports Second Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1763950/000164117225023489/ex99-1.htm)) |
| August 13, 2025 | [CNTY-101 trial start](https://sec-api.dev/pdufa/cnty-101) | IPSC | B-cell-mediated autoimmune diseases led | completed | "CARAMEL IIT study progressing towards initial patient treatment: The CARAMEL investigator-initiated trial (IIT), a Phase 1/2 trial of CNTY-101 in patients with B-cell-mediated autoimmune diseases led by Professors Georg Schett and Andreas Mackensen and sponsored by the Friedrich-Alexander University Erlangen-Nürnberg, was activated in July following the previously announced authorization of a clinical trial application (CTA) in Germany." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465925078617/tm2523439d1_ex99-1.htm)) |
| August 13, 2025 | [Century Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ipsc/catalysts) | IPSC |  | completed | "Aug. 14, 2025 -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465925078617/tm2523439d1_ex99-1.htm)) |
| August 13, 2025 | [Aura Biosciences, Inc. earnings report](https://sec-api.dev/companies/aura/catalysts) | AURA |  | completed | "Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501796/000119312525179418/aura-ex99_1.htm)) |
| August 13, 2025 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774925026511/ex_852503.htm)) |
| August 13, 2025 | [Acrivon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrv/catalysts) | ACRV |  | completed | "Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781174/000119312525179834/acrv-ex99_1.htm)) |
| August 13, 2025 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/ex99-1.htm)) |
| August 13, 2025 | [Dogwood Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dwtx/catalysts) | DWTX |  | completed | "ATLANTA, Ga., August 13, 2025 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818844/000155837025011311/dwtx-20250813xex99d1.htm)) |
| August 13, 2025 | [Enliven Therapeutics, Inc. earnings report](https://sec-api.dev/companies/elvn/catalysts) | ELVN |  | completed | "Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672619/000119312525179837/elvn-ex99_1.htm)) |
| August 13, 2025 | [Jade Biosciences, Inc. earnings report](https://sec-api.dev/companies/jbio/catalysts) | JBIO |  | completed | "Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312525179828/d82765dex991.htm)) |
| August 13, 2025 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791925000083/exhibit99106302025.htm)) |
| August 13, 2025 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000164117225023598/ex99-1.htm)) |
| August 13, 2025 | [Moleculin Biotech, Inc. earnings report](https://sec-api.dev/companies/mbrx/catalysts) | MBRX |  | completed | "Moleculin Reports Second Quarter 2025 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774925026357/ex_851330.htm)) |
| August 13, 2025 | [Perspective Therapeutics, Inc. earnings report](https://sec-api.dev/companies/catx/catalysts) | CATX |  | completed | "SEATTLE - August 13, 2025 - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/728387/000095017025107609/catx-ex99_1.htm)) |
| August 13, 2025 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Reports Second Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_ex99-1.htm)) |
| August 13, 2025 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034025000102/imrx-20250813xexx991.htm)) |
| August 13, 2025 | [Xenetic Biosciences, Inc. earnings report](https://sec-api.dev/companies/xbio/catalysts) | XBIO |  | completed | "Inc. Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316825006001/xenetic_ex9901.htm)) |
| August 13, 2025 | [Scemblix (asciminib) primary completion](https://sec-api.dev/pdufa/asciminib) | NVS | Chronic Myelogenous Leukemia - Chronic Phase | completed | "NCT05384587 (Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-13 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05384587)) |
| August 14, 2025 | [BioAffinity Technologies, Inc. earnings report](https://sec-api.dev/companies/biaf/catalysts) | BIAF |  | completed | "Technologies Reports Second Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1712762/000164117225024036/ex99-1.htm)) |
| August 14, 2025 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465925078116/tm2523508d1_ex99-1.htm)) |
| August 14, 2025 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000164117225023971/ex99-1.htm)) |
| August 14, 2025 | [Xilio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/xlo/catalysts) | XLO |  | completed | "WALTHAM, Mass., August 14, 2025 -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840233/000155837025011473/xlo-20250814xex99d1.htm)) |
| August 14, 2025 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000164117225023727/ex99-1.htm)) |
| August 14, 2025 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534525000100/exhibit99-1earningspressre.htm)) |
| August 14, 2025 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000095017025108876/tyra-ex99_1.htm)) |
| August 14, 2025 | [Annexon, Inc. earnings report](https://sec-api.dev/companies/annx/catalysts) | ANNX |  | completed | "Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1528115/000095017025108859/annx-ex99_1.htm)) |
| August 14, 2025 | [Azora Therapeutics, Inc. (DE) earnings report](https://sec-api.dev/companies/azr/catalysts) | AZR |  | completed | "2025 - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1513525/000121390025076085/ea025293001ex99-1_adial.htm)) |
| August 14, 2025 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774925026931/ex_822292.htm)) |
| August 14, 2025 | [MiNK Therapeutics, Inc. earnings report](https://sec-api.dev/companies/inkt/catalysts) | INKT |  | completed | "MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840229/000117184325005405/exh_991.htm)) |
| August 14, 2025 | [TuHURA Biosciences, Inc./NV earnings report](https://sec-api.dev/companies/hura/catalysts) | HURA |  | completed | "TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1498382/000095017025108909/hura-ex99_1.htm)) |
| August 14, 2025 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312525180890/d936404dex991.htm)) |
| August 14, 2025 | [Prelude Therapeutics Inc earnings report](https://sec-api.dev/companies/prld/catalysts) | PRLD |  | completed | "Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1678660/000095017025108413/prld-ex99_1.htm)) |
| August 14, 2025 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390025076066/ea025316301ex99-1_unicy.htm)) |
| August 14, 2025 | [Outlook Therapeutics, Inc. earnings report](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | completed | "Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm)) |
| August 14, 2025 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/ex_853315.htm)) |
| August 14, 2025 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports Second Quarter 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465925078102/tm2523504d1_ex99-1.htm)) |
| August 14, 2025 | [CYPHERPUNK TECHNOLOGIES INC. earnings report](https://sec-api.dev/companies/cyph/catalysts) | CYPH |  | completed | "Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509745/000110465925078077/tm2523408d1_ex99-1.htm)) |
| August 14, 2025 | [ROCKWELL MEDICAL, INC. earnings report](https://sec-api.dev/companies/rmti/catalysts) | RMTI |  | completed | "Rockwell Medical Announces Second Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1041024/000104102425000009/pressrelease.htm)) |
| August 14, 2025 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quarter ended June 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184325005406/exh_991.htm)) |
| August 14, 2025 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000095017025108422/pvla-ex99_1.htm)) |
| August 14, 2025 | [Phio Pharmaceuticals Corp. earnings report](https://sec-api.dev/companies/phio/catalysts) | PHIO |  | completed | "Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1533040/000168316825006171/phio_ex9901.htm)) |
| August 14, 2025 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814xex99.htm)) |
| August 14, 2025 | [Zopapogene imadenovec FDA approval](https://sec-api.dev/pdufa/zopapogene-imadenovec) | PGEN | with RRP | completed, approved | "On August 14, 2025, the FDA approved Papzimeos (zopapogene imadenovec-drba), marking the first immunotherapy approved for treatment of RRP, and the Company commenced capitalization of inventory from that date." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1356090/000135609026000009/pgen-20251231.htm)) |
| August 14, 2025 | [Valion Bio, Inc. earnings report](https://sec-api.dev/companies/vbio/catalysts) | VBIO |  | completed | "Tivic Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787740/000095017025108835/tivc-ex99_1.htm)) |
| August 14, 2025 | [Enveric Biosciences, Inc. earnings report](https://sec-api.dev/companies/envb/catalysts) | ENVB |  | completed | "Mass., August 14, 2025 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced financial results for the second quarter ended June 30, 2025, and provided a comprehensive business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/890821/000164117225023724/ex99-1.htm)) |
| August 14, 2025 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/sttk_2q2025earningsrelease.htm)) |
| August 14, 2025 | [Inhibikase Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ikt/catalysts) | IKT |  | completed | "August 14, 2025  Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (PAH), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312525180889/d946023dex991.htm)) |
| August 14, 2025 | [Biologics earnings report](https://sec-api.dev/pdufa/biologics) | HCWB |  | completed | "Miramar, FL - August 14, 2025 - HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828673/000095017025109035/hcwb-ex99_1.htm)) |
| August 14, 2025 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "2025 - Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the second quarter ended June 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/tm2523431d1_ex99-1.htm)) |
| August 14, 2025 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000095017025108448/cadl-ex99_1.htm)) |
| August 14, 2025 | [Pyxis Oncology, Inc. earnings report](https://sec-api.dev/companies/pyxs/catalysts) | PYXS |  | completed | "Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782223/000095017025108898/pyxs-ex99_1.htm)) |
| August 14, 2025 | [Rybrevant (amivantamab-vmjw) label expansion decision](https://sec-api.dev/pdufa/amivantamab-vmjw) | JNJ |  | completed, approved | "BLA761210 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20250814, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product RYBREVANT (AMIVANTAMAB-VMJW)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761210%22)) |
| August 14, 2025 | [Werewolf Therapeutics, Inc. earnings report](https://sec-api.dev/companies/howl/catalysts) | HOWL |  | completed | "Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785530/000178553025000020/a06302025ex991.htm)) |
| August 14, 2025 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, August 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2025, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000155837025011468/plx-20250814xex99d1.htm)) |
| August 14, 2025 | [SPRUCE BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/sprb/catalysts) | SPRB |  | completed | "Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1683553/000095017025108868/sprb-ex99_1.htm)) |
| August 14, 2025 | [TALPHERA, INC. earnings report](https://sec-api.dev/companies/tlph/catalysts) | TLPH |  | completed | "Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427925/000143774925026938/ex_853183.htm)) |
| August 14, 2025 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000164128125000006/bolt-ex99_1.htm)) |
| August 14, 2025 | [MeiraGTx Holdings plc earnings report](https://sec-api.dev/companies/mgtx/catalysts) | MGTX |  | completed | "LONDON and NEW YORK, August 14, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operational results for the second quarter ended June 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1735438/000155837025011478/mgtx-20250814xex99d1.htm)) |
| August 14, 2025 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Larimar Therapeutics Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000095017025108409/lrmr-ex99_1.htm)) |
| August 14, 2025 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000164117225023740/ex99-1.htm)) |
| August 14, 2025 | [ELITE PHARMACEUTICALS INC /NV/ earnings report](https://sec-api.dev/companies/eltp/catalysts) | ELTP |  | completed | "Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053369/000164117225024088/ex99-1.htm)) |
| August 14, 2025 | [Anaphylm™ (dibutepinephrine) FDA approval](https://sec-api.dev/pdufa/dibutepinephrine) | AQST |  | completed, approved | "WARREN, N.J., August 14, 2025 - Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP ("RTW"), subject to United States Food and Drug Administration (FDA) approval of Anaphylm™ (epinephrine) Sublingual Film and other conditions." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000114036125031008/ef20053941_ex99-1.htm)) |
| August 14, 2025 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000164117225023715/ex99-1.htm)) |
| August 14, 2025 | [ABVC BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/abvc/catalysts) | ABVC |  | completed | "BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, central nervous system (CNS) disorders, and oncology/hematology, today announced its financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1173313/000121390025076018/ea025308601ex99-1_abvcbio.htm)) |
| August 14, 2025 | [Traws Pharma, Inc. earnings report](https://sec-api.dev/companies/traw/catalysts) | TRAW |  | completed | "Pharma Reports Second Quarter 2025 Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1130598/000110465925078060/tm2523498d1_ex99-1.htm)) |
| August 14, 2025 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports Financial Results for the quarter ended June 30, 2025 and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036125031041/ef20053791_ex99-1.htm)) |
| August 14, 2025 | [Camp4 Therapeutics Corp earnings report](https://sec-api.dev/companies/camp/catalysts) | CAMP |  | completed | "CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1736730/000173673025000068/camp4-q2xearningsxreleasef.htm)) |
| August 14, 2025 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000095017025108426/lxeo-ex99_1.htm)) |
| August 14, 2025 | [Zura Bio Ltd earnings report](https://sec-api.dev/companies/zura/catalysts) | ZURA |  | completed | "August 14, 2025 - Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855644/000110465925078142/tm2522624d1_ex99-1.htm)) |
| August 14, 2025 | [Lazcluze (lazertinib mesylate) label expansion decision](https://sec-api.dev/pdufa/lazertinib) | JNJ |  | completed, approved | "NDA219008 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250814, review_priority STANDARD; sponsor_name JANSSEN BIOTECH; product LAZCLUZE (LAZERTINIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219008%22)) |
| August 14, 2025 | [Cendakimab primary completion](https://sec-api.dev/pdufa/cendakimab) | BMY | Eosinophilic Esophagitis | completed | "NCT04991935 (Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-04-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04991935)) |
| August 14, 2025 | [TTI-101 primary completion](https://sec-api.dev/pdufa/tti-101) | TVRD | Idiopathic Pulmonary Fibrosis | completed | "NCT05671835 (Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Tvardi Therapeutics, Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05671835)) |
| August 14, 2025 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Hidradenitis Suppurativa | completed | "NCT06411379 (Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06411379)) |
| August 14, 2025 | [LY3549492 primary completion](https://sec-api.dev/pdufa/ly3549492) | LLY | Healthy | withdrawn | "NCT07085468 (A Study of LY3549492 in Healthy Weight Adult Participants): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07085468)) |
| August 15, 2025 | [Tonix Pharmaceuticals Holding Corp. PDUFA date](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | scheduled | "PDUFA goal date August 15, 2025, with potential US commercial launch in Q4 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125009199/ex99-01.htm)) |
| August 15, 2025 | [Levosimendan PDUFA date](https://sec-api.dev/pdufa/levosimendan) | TNXP |  | completed, approved | "FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for fibromyalgia: if approved by FDA, TNX-102 SL would be the first new drug for fibromyalgia in more than 16 years" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125011053/ex99-01.htm)) |
| August 15, 2025 | [Levosimendan FDA approval](https://sec-api.dev/pdufa/levosimendan) | TNXP | fibromyalgia in adults | completed, approved | "Holding Corp. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") approved TonmyaTM (cyclobenzaprine HCl sublingual tablets), which was investigated as TNX-102 SL, for the treatment of fibromyalgia in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1430306/000199937125011478/tnxp_8k-081525.htm)) |
| August 15, 2025 | [Tonmya (cyclobenzaprine hydrochloride) FDA approval](https://sec-api.dev/pdufa/cyclobenzaprine) | TNXP |  | completed, approved | "NDA219428 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250815, review_priority STANDARD; sponsor_name TONIX; product TONMYA (CYCLOBENZAPRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219428%22)) |
| August 15, 2025 | [TONMYA (tonmya) FDA approval](https://sec-api.dev/pdufa/tonmya) | TNXP | fibromyalgia in adults | completed, approved | "On August 15, 2025, the U.S. Food and Drug Administration approved Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, the first new fibromyalgia therapy in more than 15 years" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125014216/ex99-01.htm)) |
| August 15, 2025 | [BGE-102 trial start](https://sec-api.dev/pdufa/bge-102) | BIOA |  | completed | "On August 15, 2025, we announced that the first patient was dosed in our Phase 1 SAD / MAD clinical trial for BGE-102." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120873/bioa-20251231.htm)) |
| August 15, 2025 | [Tonix Pharmaceuticals Holding Corp. FDA approval](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed, approved | "© 2025 Tonix Pharmaceuticals Holding Corp. 7 FDA Approved on August 15, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937125014776/ex99-01.htm)) |
| August 15, 2025 | [AJOVY® (fremanezumab) primary completion](https://sec-api.dev/pdufa/fremanezumab) | TEVA | Migraine | completed | "NCT04530110 (A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC; Results First Posted 2026-07-24." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530110)) |
| August 15, 2025 | [IGALMI® (dexmedetomidine) primary completion](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ | Agitation,Psychomotor; Bipolar I Disorder; Bipolar II Disorder | completed | "NCT05658510 (Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor BioXcel Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05658510)) |
| August 15, 2025 | [Amniotic suspension allograft primary completion](https://sec-api.dev/pdufa/amniotic-suspension-allograft) | ORGO | Knee Osteoarthritis | completed | "NCT06000410 (A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-15 (ACTUAL); Lead Sponsor Organogenesis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06000410)) |
| August 15, 2025 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO | moderate to advanced liver fibrosis | completed, approved | "Bagsv&aelig;rd, Denmark, 15 August 2025 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000117184325005454/f6k_081525.htm)) |
| August 17, 2025 | [Baxfendy (baxdrostat) primary completion](https://sec-api.dev/pdufa/baxdrostat) | AZN | Resistant Hypertension | completed | "NCT06168409 (A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-17 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-08-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06168409)) |
| August 18, 2025 | [Clemidsogene lanparvovec PDUFA date](https://sec-api.dev/pdufa/clemidsogene-lanparvovec) | RGNX | Mucopolysaccharidosis II | scheduled | "On August 18, 2025, REGENXBIO Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has extended the Prescription Drug User Fee Act ("PDUFA") date for the Company's Biologics License Application seeking accelerated approval of clemidsogene lanparvovec (RGX-121) for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1590877/000095017025109829/rgnx-20250818.htm)) |
| August 18, 2025 | [NEONC TECHNOLOGIES HOLDINGS, INC. earnings report](https://sec-api.dev/companies/nthi/catalysts) | NTHI |  | completed | "NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1979414/000182912625006673/neonctechnologies_ex99-1.htm)) |
| August 18, 2025 | [Modeyso (dordaviprone) PDUFA date](https://sec-api.dev/pdufa/dordaviprone) | JAZZ |  | scheduled | "Dordaviprone is currently under Priority Review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) action date set for August 18, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1232524/000119312525087233/d887871dex991.htm)) |
| August 18, 2025 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000175392625001353/g084926_ex99-1.htm)) |
| August 18, 2025 | [FAYUVI (rebisufligene etisparvovec) PDUFA date](https://sec-api.dev/pdufa/rebisufligene-etisparvovec) | RARE |  | completed, complete response letter | "UX111, an investigational treatment for Sanfilippo syndrome, biologics license application (BLA) on track for PDUFA action date of August 18, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-ex99_1.htm)) |
| August 18, 2025 | [NRX Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/nrxp/catalysts) | NRXP |  | completed | "WILMINGTON, Del., August 18th, 2025 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended June 30, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719406/000143774925027256/ex_854273.htm)) |
| August 18, 2025 | [REC-2282 primary completion](https://sec-api.dev/pdufa/rec-2282) | RXRX | Neurofibromatosis Type 2 | withdrawn | "NCT05130866 (Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2025-08-18 (ACTUAL); Lead Sponsor Recursion Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05130866)) |
| August 18, 2025 | [Rp2 primary completion](https://sec-api.dev/pdufa/rp2) | REPL | Refractory Metastatic Colorectal Cancer; pMMR; MSS | withdrawn | "NCT05733611 (RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-08-18 (ACTUAL); Lead Sponsor Replimune, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05733611)) |
| August 18, 2025 | [Nda220049 complete response letter (CRL)](https://sec-api.dev/pdufa/nda220049) | PTCT |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220049_20250818.pdf%22)) |
| August 19, 2025 | [PTC THERAPEUTICS, INC. PDUFA date](https://sec-api.dev/companies/ptct/catalysts) | PTCT |  | scheduled | "NDA reviews for vatiquinone (Friedreich's ataxia) and Translarna (nonsense mutation DMD) are ongoing, with regulatory action date of August 19, 2025 for vatiquinone" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000155837025010770/tmb-20250807xex99d1.htm)) |
| August 19, 2025 | [VK2735 topline data readout](https://sec-api.dev/pdufa/vk2735) | VKTX |  | completed, positive | "SAN DIEGO, CA - August 19, 2025 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1607678/000160767825000003/vktx-ex99_1.htm)) |
| August 19, 2025 | [Cingulate Inc. earnings report](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed | "Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000164117225024741/ex99-1.htm)) |
| August 19, 2025 | [Vatiquinone complete response letter (CRL)](https://sec-api.dev/pdufa/vatiquinone) | PTCT | children and adults living with Friedreich's ataxia | completed, complete response letter | "WARREN, N.J., August 19, 2025 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1070081/000155837025011658/tmb-20250819xex99d1.htm)) |
| August 19, 2025 | [Vatiquinone PDUFA date](https://sec-api.dev/pdufa/vatiquinone) | PTCT |  | completed, complete response letter | "In February 2025, the FDA accepted for filing the NDA and granted priority review with a target regulatory action date of August 19, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1070081/000155837025010796/tmb-20250630x10q.htm)) |
| August 19, 2025 | [OS Therapies Inc earnings report](https://sec-api.dev/companies/ostx/catalysts) | OSTX |  | completed | "Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported second quarter 2025 financial results ended June 30, 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1795091/000121390025078152/ea025371101ex99-1_ostherap.htm)) |
| August 19, 2025 | [REGENERON PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/regn/catalysts) | REGN |  | scheduled | "The FDA target action date is August 19, 2025, following the use of a priority review voucher." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000180422025000020/exhibit991q12025.htm)) |
| August 19, 2025 | [SKYCLARYS® (omaveloxolone) PDUFA date](https://sec-api.dev/pdufa/omaveloxolone) | LRMR | children and adults living with FA | scheduled | "The FDA has accepted for filing PTC's NDA for vatiquinone for the treatment of children and adults living with FA with a target action date of August 19, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1374690/000095017025043925/lrmr-20241231.htm)) |
| August 19, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Hepatocellular | withdrawn | "NCT04246177 (Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-08-19 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04246177)) |
| August 19, 2025 | [Carbetocin primary completion](https://sec-api.dev/pdufa/carbetocin) | ACAD | Hyperphagia in Prader-Willi Syndrome | completed | "NCT06173531 (Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-19 (ACTUAL); Lead Sponsor ACADIA Pharmaceuticals Inc.; Results First Posted 2026-10-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06173531)) |
| August 20, 2025 | [IMCIVREE® (setmelanotide) NDA/BLA acceptance](https://sec-api.dev/pdufa/setmelanotide) | RYTM | conditions associated with acquired hypothalamic obesity | completed | "On August 20, 2025, Rhythm announced that the U.S. Food and Drug Administration (FDA) accepted for filing the Company's sNDA for setmelanotide seeking approval for the treatment of conditions associated with acquired hypothalamic obesity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465925105904/rytm-20251104xex99d1.htm)) |
| August 20, 2025 | [IGALMI® (dexmedetomidine) NDA/BLA submission](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | scheduled | "The primary purpose of the pre-sNDA meeting, scheduled for August 20, 2025, is to gain alignment with the FDA regarding the content and format of the planned sNDA submission, which the Company is preparing." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1720893/000110465925069149/tm2521267d1_8k.htm)) |
| August 21, 2025 | [DAWNZERA™ (donidalorsen) FDA approval](https://sec-api.dev/pdufa/donidalorsen) | IONS |  | completed, approved | "On August 21, 2025, Ionis Pharmaceuticals, Inc. ("Ionis," "we," "us" or "our company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has approved DAWNZERA™ (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema ("HAE") in adult and pediatric patients 12 years of age and older." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/874015/000114036125032176/ef20054334_8k.htm)) |
| August 21, 2025 | [Aldeyra Therapeutics, Inc. NDA/BLA submission](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | completed | "Per the FDA's earlier request during the NDA review, the safety data from the field trial was submitted to the NDA on August 21, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm)) |
| August 21, 2025 | [DAWNZERA™ (donidalorsen) PDUFA date](https://sec-api.dev/pdufa/donidalorsen) | IONS |  | completed, approved | "Donidalorsen on track to launch this year, assuming approval, with a U.S. PDUFA date of August 21, 2025 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_ex99-1.htm)) |
| August 21, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06224348 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-21 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06224348)) |
| August 21, 2025 | [MRNA-1010 primary completion](https://sec-api.dev/pdufa/mrna-1010) | MRNA | Seasonal Influenza | completed | "NCT06602024 (A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-21 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602024)) |
| August 22, 2025 | [GTX-104 NDA/BLA acceptance](https://sec-api.dev/pdufa/gtx-104) | GRCE |  | completed | "On August 22, 2025, the FDA accepted the Company's NDA for GTx-104 for formal review, establishing April 23, 2026 as its PDUFA target date." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_ex99-1.htm)) |
| August 22, 2025 | [PAVBLU® (aflibercept) interim data readout](https://sec-api.dev/pdufa/aflibercept) | FDMT |  | completed, positive | "Announced positive long-term interim results (data cutoff: August 22, 2025)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-ex99_1.htm)) |
| August 22, 2025 | [LN-145 primary completion](https://sec-api.dev/pdufa/ln-145) | IOVA | Cervical Carcinoma | withdrawn | "NCT03108495 (Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Iovance Biotherapeutics, Inc.; Results First Posted 2026-07-31." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03108495)) |
| August 22, 2025 | [ZANVASTRO™ (zilganersen) primary completion](https://sec-api.dev/pdufa/zilganersen) | IONS | Alexander Disease | completed | "NCT04849741 (A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04849741)) |
| August 22, 2025 | [MEDI-546 primary completion](https://sec-api.dev/pdufa/medi-546) | AZN | Systemic Lupus Erythematosus | completed | "NCT04877691 (Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04877691)) |
| August 22, 2025 | [1h incubation photodynamic therapy (pdt) (ala-pdt, ameluz®-pdt) primary completion](https://sec-api.dev/pdufa/1h-incubation-photodynamic-therapy-pdt-ala-pdt-ameluz-pdt) | BFRI | Acne Vulgaris | completed | "NCT05080764 (Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Biofrontera Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05080764)) |
| August 22, 2025 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes | completed | "NCT06045221 (A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Eli Lilly and Company; Results First Posted 2026-09-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06045221)) |
| August 25, 2025 | [ARGENX SE topline data readout](https://sec-api.dev/companies/argx/catalysts) | ARGX |  | completed, positive | "Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline data from the pivotal ADAPT SERON study of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465925082118/tm2524211d1_ex99-1.htm)) |
| August 25, 2025 | [Dato-dxd primary completion](https://sec-api.dev/pdufa/dato-dxd) | AZN | Breast Cancer | completed | "NCT05374512 (A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05374512)) |
| August 25, 2025 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Migraine | completed | "NCT05810038 (A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-09-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05810038)) |
| August 25, 2025 | [Vaxcyte, Inc. primary completion](https://sec-api.dev/companies/pcvx/catalysts) | PCVX | Pneumococcal Vaccines | completed | "NCT05844423 (Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05844423)) |
| August 26, 2025 | [Luveltamab tazevibulin primary completion](https://sec-api.dev/pdufa/luveltamab-tazevibulin) | STRO | Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer | withdrawn | "NCT05870748 (REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2025-08-26 (ACTUAL); Lead Sponsor Sutro Biopharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05870748)) |
| August 26, 2025 | [PAVBLU® (aflibercept) primary completion](https://sec-api.dev/pdufa/aflibercept) | REGN | Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema | completed | "NCT06491914 (A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-26 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06491914)) |
| August 27, 2025 | [Zopapogene imadenovec PDUFA date](https://sec-api.dev/pdufa/zopapogene-imadenovec) | PGEN |  | completed, approved | "The United States Food and Drug Administration ("FDA") granted priority review to a Biologics License Application ("BLA") for PRGN-2012 with a Prescription Drug User Fee Act ("PDUFA") target action date set for August 27, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1356090/000135609025000024/pgen-20250630.htm)) |
| August 27, 2025 | [Outlook Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/otlk/catalysts) | OTLK |  | scheduled | "The FDA set a PDUFA goal date of August 27, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm)) |
| August 27, 2025 | [Girentuximab PDUFA date](https://sec-api.dev/pdufa/girentuximab) | TLX |  | scheduled | "The FDA accepted the Biologics License Application (BLA) for Telix's kidney cancer imaging candidate TLX250-CDx (Zircaix®15, 89Zr-DFO-girentuximab), granted a Priority Review, and provided a PDUFA16 goal date of 27 August 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007191/000200719125000047/q1bizupdate.htm)) |
| August 27, 2025 | [Nimodipine NDA/BLA acceptance](https://sec-api.dev/pdufa/nimodipine) | GRCE |  | completed | "Princeton, NJ, August 27, 2025 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that on August 22, 2025 the U.S. Food and Drug Administration (FDA) accepted the Company's New Drug Application (NDA) for GTx-104 for formal review." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1444192/000114036125032847/ef20054617_ex99-1.htm)) |
| August 27, 2025 | [Nuvaxovid (nuvaxovid) FDA approval](https://sec-api.dev/pdufa/nuvaxovid) | NVAX | COVID-19 in individuals 65 years of age and older, or 12 years | completed, approved | "Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™ 2025-2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1000694/000110465925084049/tm2524511d2_ex99-1.htm)) |
| August 27, 2025 | [PRECIGEN, INC. PDUFA date](https://sec-api.dev/companies/pgen/catalysts) | PGEN | with Recurrent Respiratory Papillomatosis | scheduled | "Company's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010325006004/dp228863_ex9901.htm)) |
| August 27, 2025 | [COMIRNATY (comirnaty) label expansion decision](https://sec-api.dev/pdufa/comirnaty) | BNTX |  | completed, approved | "NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.2" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776985/000177698525000053/a991250827_covid-19lp815fd.htm)) |
| August 27, 2025 | [MVASI® (bevacizumab) complete response letter (CRL)](https://sec-api.dev/pdufa/bevacizumab) | OTLK | wet AMD | completed, complete response letter | "Inc (the "Company") issued a press release announcing that it has completed the requested Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649989/000110465925094558/tm2527376d1_8k.htm)) |
| August 27, 2025 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | OTLK |  | completed, complete response letter | "U.S. Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is August 27, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_ex99-1.htm)) |
| August 27, 2025 | [PHIBRO ANIMAL HEALTH CORP earnings report](https://sec-api.dev/companies/pahc/catalysts) | PAHC |  | completed | "TEANECK, N.J., August 27, 2025 (Business Wire) - Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069899/000155837025011778/pahc-20250827xex99d1.htm)) |
| August 27, 2025 | [Expec9v primary completion](https://sec-api.dev/pdufa/expec9v) | JNJ | Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention | completed | "NCT04899336 (A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-27 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04899336)) |
| August 27, 2025 | [FILSPARI (sparsentan) label expansion decision](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "NDA216403 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250827, review_priority STANDARD; sponsor_name TRAVERE; product FILSPARI (SPARSENTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216403%22)) |
| August 28, 2025 | [FILSPARI (sparsentan) NDA/BLA acceptance](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | scheduled | "Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA target action date of August 28, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/aex991_2024q4xearningsprex.htm)) |
| August 28, 2025 | [FILSPARI (sparsentan) PDUFA date](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "•The FDA assigned a PDUFA target action date of August 28, 2025, to the Company's supplemental New Drug Application (sNDA) requesting modification of liver monitoring for FILSPARI in IgAN." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/aex991_2024q4x10xkearnings.htm)) |
| August 28, 2025 | [Pgn-edo51 primary completion](https://sec-api.dev/pdufa/pgn-edo51) | PEPG | Duchenne Muscular Dystrophy | withdrawn | "NCT06079736 (A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-08-28 (ACTUAL); Lead Sponsor PepGen Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079736)) |
| August 28, 2025 | [Obexelimab primary completion](https://sec-api.dev/pdufa/obexelimab) | ZBIO | Relapsing Multiple Sclerosis | completed | "NCT06564311 (A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-28 (ACTUAL); Lead Sponsor Zenas BioPharma (USA), LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06564311)) |
| August 29, 2025 | [Otezla (apremilast) FDA approval](https://sec-api.dev/pdufa/apremilast) | AMGN |  | completed, approved | "NDA210745 ORIG-2 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250829, review_priority STANDARD; sponsor_name AMGEN INC; product OTEZLA (APREMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210745%22)) |
| August 29, 2025 | [Wayrilz (rilzabrutinib) PDUFA date](https://sec-api.dev/pdufa/rilzabrutinib) | SNY |  | completed, approved | "Rilzabrutinib is currently under regulatory review in the US and the EU, with a US Food and Drug Administration target action date of August 29, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000119312524278124/d913939dex992.htm)) |
| August 29, 2025 | [BEQALZI™ (sonrotoclax) topline data readout](https://sec-api.dev/pdufa/sonrotoclax) | ONC | relapsed/refractory mantle cell lymphoma | completed, positive | "On August 29, 2025, we announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory mantle cell lymphoma, following treatment with a Bruton's tyrosine kinase inhibitor ("BTKi") and anti-CD20 therapy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000162828025049824/bgne-20250930.htm)) |
| August 29, 2025 | [Wayrilz (rilzabrutinib) FDA approval](https://sec-api.dev/pdufa/rilzabrutinib) | SNY |  | completed, approved | "Wayrilz \| rilzabrutinib \| 8/29/2025 \| To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroidsDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| August 30, 2025 | [Zw25 (zanidatamab) primary completion](https://sec-api.dev/pdufa/zw25-zanidatamab) | JAZZ |  | completed | "NCT03929666 (A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-30 (ACTUAL); Lead Sponsor Jazz Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03929666)) |
| August 31, 2025 | [CAPRICOR THERAPEUTICS, INC. PDUFA date](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | scheduled | "In early 2025, the FDA accepted the application for review, granted Priority Review status, and assigned a Prescription Drug User Fee Act ("PDUFA") target action date of August 31, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1133869/000110465925109298/capr-20250930x10q.htm)) |
| August 31, 2025 | [LEQEMBI (lecanemab) PDUFA date](https://sec-api.dev/pdufa/lecanemab) | BIIB |  | scheduled | "•In January 2025 the FDA accepted for review the BLA for LEQEMBI subcutaneous autoinjector for weekly maintenance dosing, with a PDUFA action date set for August 31, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504525000033/biib-20250630.htm)) |
| August 31, 2025 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, complete response letter | "Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513xex99d1.htm)) |

Other months: https://sec-api.dev/fda-calendar/2025-07 , https://sec-api.dev/fda-calendar/2025-09. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates August 2025: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2025-08

```bibtex
@misc{secapidev_fda_calendar_2025_08_20261116,
  title        = {PDUFA dates August 2025: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2025-08}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2025_08_20261116","title":"PDUFA dates August 2025: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2025-08","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
